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To my family

“The world is full of obvious things 
which nobody by any chance ever observes.” 
Arthur Conan Doyle 
  
 
  
ABSTRACT 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition that may occur 
in connection with pregnancy, when maternal antibodies directed against paternally inherited 
platelet antigens cross the placenta and mediate thrombocytopenia in the fetus and neonate. 
FNAIT puts the fetus at risk of severe bleedings, with an intracranial hemorrhage being the 
most feared outcome. Antibodies targeting Human Platelet Antigen 1a (HPA-1a) are the most 
common cause of FNAIT in Caucasians, and several mechanisms may potentially be 
involved. The overall aim of this thesis was to use both clinical and experimental data to 
investigate possible mechanisms of FNAIT, and to evaluate the impact of FNAIT on neonatal 
morbidity in Sweden by investigating the frequency of maternal platelet alloimmunization in 
newborns diagnosed with an intracranial hemorrhage (ICH).  
In study I and II, the presence of anti-HLA class I antibodies in relation to FNAIT is 
investigated. Anti-HLA class I antibodies are a common occurrence after pregnancy, and the 
only serological finding in many cases of suspected FNAIT. Platelets express HLA class I 
antigen, and it has for long been debated whether anti-HLA class I antibodies could cause 
FNAIT. Based on national referrals in Sweden and Norway, we identified cases of suspected 
FNAIT where only anti-HLA class I antibodies could be detected. We compared anti-HLA 
class I antibody specificities and levels in these referred cases to controls, and found that the 
included cases in both studies had higher antibody levels compared to the control groups, and 
that especially antibodies against HLA-B antigens stood out with high levels. In study II, 
genotyping of the maternal and neonatal HLA class I alleles could untangle seemingly broad 
antibody specificity patterns, as mapping of epitopes revealed that the antibodies were in fact 
largely specific against paternal epitopes, expressed on multiple antigens. There was only 
weak correlations between anti-HLA class I antibody levels and clinical outcome, and 
especially in study I, a majority of cases were found to have other factors that could 
contribute to thrombocytopenia. In study III, we investigated platelet function in adult and 
neonatal blood, and the effects of anti-HPA-1a antibodies on platelet function. We found that 
umbilical cord blood was characterized by a pronounced decrease in platelet aggregation, a 
reduced change in expression of glycoproteins with activation, and an enhanced primary 
hemostasis, compared to adult peripheral blood. The presence of a monoclonal anti-HPA-1a 
antibody reduced fibrinogen binding to HPA-1a positive platelets, but with limited functional 
consequences, as measured by flow cytometry. For study IV, we investigated the frequency 
of maternal platelet alloimmunization in clinically recognized cases of neonatal ICH. Using 
the Swedish Neonatal Quality register, we identified 286 neonates registered with ICH born 
at or from 32 weeks of gestation, and ultimately included 105 maternal samples for analysis. 
We found two HPA-1a antigen negative (HPA-1bb) mothers, of which one had detectable 
anti-HPA-1a antibodies and a severely thrombocytopenic neonate. Two other mothers had 
detectable antibodies (anti-HPA-5b and anti-HPA-15a) and neonates with moderate 
thrombocytopenia. The available clinical data revealed a high frequency of other factors with 
a known association to ICH, and the study suggests a lower frequency of ICH associated with 
FNAIT than previously estimated in prospective studies. Overall, these studies confirm the 
notion of FNAIT as a heterogeneous condition, with findings that may inform future studies 
on frequency of severe FNAIT, and potential mechanisms.  
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1 INTRODUCTION 
 
1.1 A BIRD’S EYE VIEW OF FETAL AND NEONATAL ALLOIMMUNE 
THROMBOCYTOPENIA 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare condition with an 
estimated incidence of 1:1000-2000 live births[1-4]. During pregnancy, maternal 
alloantibodies targeting fetal antigens inherited from the father cross the placenta and mediate 
thrombocytopenia in the fetus and newborn, resulting in an increased risk of bleedings. The 
antibody specificities that cause FNAIT vary in different populations, and in Caucasians 
FNAIT is most commonly caused by antibodies targeting human platelet antigen 1a (HPA-
1a)[5]. Cases of neonatal thrombocytopenia in the presence of these maternal alloantibodies 
were first described in the early 1960’s[6]. Today, the immunobiology and pathophysiology 
of FNAIT is still not completely understood. The exact incidence and natural history of 
FNAIT is also unknown because most screening programs have included interventions to 
avoid serious complications, such as an intracranial hemorrhage[7]. No country has 
implemented any prenatal screening program to prevent FNAIT due to the unknown true 
incidence of severe FNAIT, and lack of interventions such as targeted therapy and 
prophylaxis. However, large efforts are going into developing a prophylaxis[8], and screening 
studies are ongoing in Poland[9], and planned in the Netherlands (the HPA-screening In 
Pregnancy study), with the aims to determine the frequency of severe FNAIT, and pave the 
way for future screening programs. The large resources going into these efforts, together with 
the potential severe consequences of FNAIT, justifies further research on this condition. The 
main focus of this introduction is the possible immunological mechanisms of FNAIT, and 
what is learned from clinical data so far. 
Figure 1: The Basic Concept of FNAIT. Recognition of fetal platelet antigens by the maternal immune 
system leads to transport of maternal anti-platelet antibodies across the placenta, mediating thrombocytopenia 
and increased risk of bleedings in the fetus and neonate. Adapted from [10]. 
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1.2 AN OVERVIEW OF ANTIGEN RECOGNITION AND ANTIBODY 
PRODUCTION 
An essential ability of the immune system is to distinguish self from non-self, and protect 
against foreign, and potentially damaging, antigens by eliminating or neutralizing them. At 
the heart of this ability lies antigen recognition and antibody production. To avoid launching 
an attack against the body’s own cells, each step in this process is controlled by the 
requirement of co-stimulatory signals, either from interaction with other immune cells, or by 
means of “danger signals” – which can be produced by cells under stress, or expressed by 
exogenous pathogens.  
Lymphocytes, in particular B- and T-cells, orchestrate the antibody response against antigens, 
which are defined as a molecules that can bind to an antibody or T-cell receptor. Briefly, an 
antigen will first be encountered and processed by antigen presenting cells (APCs). 
Depending on properties of the antigen and signals from the surrounding milieu, the APC can 
become activated, enhance its presentation of the antigen, and travel to the lymph node. The 
lymph node functions as a meeting point, where several APCs can present multiple antigens 
encountered throughout the body to mature T-cells. The APCs present the processed antigen 
on its surface to T-cells, which can have receptors specific for the encountered antigen. If a T-
cell recognizes the same particular antigen, and also receives co-stimulatory signals from the 
activated APC, this can trigger activation of the T-cell. The T-cell will then in turn activate 
the antigen-specific B-cell, which will lead to an expansion of this B-cell clone. With help 
from T-cells, the clone expressing the B-cell receptor with the highest affinity towards the 
antigen will survive and develop into an efficient antibody-producing plasma cell. These cells 
reside for long periods of time in the body, producing antibodies directed against the antigen; 
in case of new encounters with the same antigen, the immune system is rapidly able to mount 
an efficient response.      
T-cells are crucial for both controlling and enhancing the response against antigens. Antigens 
are presented to T-cells in two ways; endogenous peptides can be presented by any cell 
expressing HLA class I molecules, and “professional antigen presenting cells”, such as 
dendritic cells, B-cells and macrophages, can process and present peptide fragments of the 
antigen on HLA class II molecules. The T-cell receptor (TCR) can recognize a magnitude of 
antigens as it is encoded by genes assembled after somatic re-arrangement of germ-line 
encoded gene elements (known as V(D)J recombination). A few hundred germ-line gene 
elements can generate millions of different antigen receptors, with potentially equal number 
of specificities. The T-cells undergo positive and negative selection in the thymus, which 
ensures binding of self-antigens with an adequate affinity, to be functional and self-tolerant 
T-cells. The surviving “naïve” (CD4+CD8+) T-cell can then develop into CD8+ T-cells or 
CD4+, depending on whether the T-cell receptor recognizes HLA class I or II, respectively. 
CD8+ T-cells are also known as cytotoxic T-cells, important in the defense against viruses 
and cancer. CD4+ T-cells can stimulate B-cells, and is part of the humoral response. Both 
require co-stimulatory signals, together with binding of TCR to antigen presented on their 
respective HLA molecule, to be activated, and signals from co-stimulatory molecules and 
cytokines will stimulate differentiation into various subtypes of T-cells.  
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For antibody production, antigen-presenting cells (APCs) that have encountered and 
processed an antigen, will typically travel to the lymph node and encounter a T-cell with a 
TCR for the specific antigen. During the process of developing from an “antigen-capturing” 
to an antigen-presenting cell, the APC will express cytokines and co-stimulatory molecules, 
to become an activated APC that can interact with the T-cell. The binding of the specific 
TCR to HLA class II-bound peptide on the APC, will together with binding of CD4, which 
binds to a different part of the HLA class II molecule, lead to phosphorylation and activate 
intracellular pathways of the T-cell (signal 1). A second stimulatory signal is necessary for 
the T-cell to become activated: CD80 or CD86, expressed on activated APC, bind CD28 on 
CD4+ T-cells, which alters the intracellular signals for the T-cells, ultimately allowing for 
activation. This two-step activation leads to proliferation of the T-cell, and in future 
encounters with the same antigen, only the first signal is necessary for activation of the T-
cell. Activation leads to release of IL-2, which stimulates the T-cell in an autocrine manner, 
and leads to a clonal expansion of the T-cell.  
A naïve B-cell, which have yet to encounter its specific antigen, will express a mature B-cell 
receptor (BCR), consisting of a trans-membrane protein, and a surface bound 
immunoglobulin, which can be shed as an antibody (IgM/D). Similarly to T-cells, the genes 
encoding the B-cell receptor also undergo V(D)J recombination, allowing for heterogeneity 
of the antigen-binding site. There are several thousands of copies of BCRs on the B-cell 
surface, and upon binding of the antigen, the BCRs can cluster together and signal for 
activation of the B-cell[11]. As mentioned earlier, B-cells can also present antigen to T-cells, 
by processing the antigen and present it on HLA class II, leading to further activation of both 
lymphocytes[12]. Different antigens can be divided by these two mechanisms for B-cell 
activation: T-cell independent antigens stimulate the B-cell by pattern recognition receptors, 
such as as toll-like receptors that recognize “danger signals” expressed on the antigen surface, 
or by cross-linking of the BCRs[13], while T-cell dependent antigens require co-stimulatory 
signals such as CD40-CD40L interaction, and subsequent release of IL-4 from CD4+ T-cells 
will further stimulate the differentiation of the activated B-cell into plasma cells. In addition, 
complement can enhance B-cell activation and antibody production[14], by signaling through 
the CR2 complex (which binds C3d bound to the antigen).  
The production of antibodies induced by T-cell dependent antigens is a two-step process[15]: 
As a rapid, “extra-follicular”, response, B-cells receive an antigen-dependent signal that leads 
to the development of plasmablasts that divide, and may undergo immunoglobulin class 
switching. However, these cells are short-lived, and there is little somatic hypermutation. The 
second step ensures the production of high-affinity antibodies: The majority of mature B-cells 
reside in follicles of secondary lymphoid organs as follicular B cells, where they can be 
exposed to antigens by follicular dendritic cells. With support of follicular B helper T cells 
(TFH), antigen-activated B-cells can form germinal centers and undergo further modification 
of the BCR genes by somatic hypermutation. Somatic hypermutation of the BCR genes 
changes the affinity to the antigen, and B cell clones with a high affinity will by the help of 
TFH be selected to undergo class switching (as IgM to IgG), and ultimately differentiate into 
“effector B-cells”; plasma cells, which will secrete high-affinity antibodies and may persist as 
long-lived cells[16], and memory B-cells, both likely important for an efficient secondary 
immune response[17].  
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The body produces 1012 antibodies per day (Wermeling F, Basic Immunology lecture notes, 
2015). IgG has a half-life of approximately 20 days, and is the most abundant in human 
serum of the five immunoglobulin isotypes (IgA, IgD, IgE, IgM, IgG)[18]. IgG can be 
divided into four subclasses (IgG1-4). The subclasses differ in their constant regions, which 
are involved in IgG binding (such as to FcγR and C1q); different subclasses of IgG can 
therefore have different effector functions, such as triggering FcγR expressing cells, leading 
to phagocytosis or antibody-dependent cell-mediated cytotoxicity (ADCC), and activating 
complement[19]. 
 
 
 
Figure 2: Overview of the generation of antibodies from antigen-activated B-cells. Activated B-cells 
differentiate into centroblast. Somatic hypermutation (SHM) introduces base-pair changes in the V(D)J 
segments that encode the variable regions of the immunoglobulin heavy and light chain. Centroblasts further 
differentiate into centrocytes, where they can be selected by T-cells on the basis of their improved receptor 
binding to the antigen. Centroblasts and centrocytes cycle between dark and light zone. Centrocytes with 
inadequate binding to the antigen undergo apoptosis, and only a subset of the centrocytes undego class-switch 
recombination (CSR), and eventually differentiate into plasma cells or memory B cells. Adapted from[20]. 
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1.3 MATERNAL TOLERANCE OF THE FETUS DURING PREGNANCY 
The fetus is semi-allogeneic – meaning it inherits both antigens from the father, which the 
mother’s immune system can recognize as non-self, and antigens from the mother, which will 
be recognized as self. To allow for a developing semi-allogeneic fetus while simultaneously 
upholding responses required for immunity, the maternal immune system needs unique 
qualities, most of which are still unknown. 
Likely, there is a site-specific inhibition of the maternal immune system at the placenta, that 
allows for maternal tolerance[21]. Briefly, mechanisms may include: Fetal expression of 
FasL, which can induce T-cell apoptosis[22]; expression of HLA-G and HLA-C on 
extravillous trophoblast cells (EVTs), which may respectively serve as ligand for inhibitory 
NK cell receptors (such as KIR2DL4)[23], and modulate decidual NK cell response to 
invading trophoblast[24]; release of immunosuppressive molecules such as indoleamine 2,3-
dioxygenase (IDO), depleting T-cells of tryptophan and dampening their response [25]; 
entrapment of antigen-presenting dendritic cells in the decidua[26].  
However, the invading placenta is not the only site where fetal tolerance needs to be upheld: 
Fetal cells enter the maternal circulation and can persist for decades[27, 28], a phenomena 
known as fetal microchimerism. (Reciprocally, maternal cells enter fetal circulation (maternal 
microchimerism), where they may persist into adulthood[29]). The presence of these fetal 
cells likely requires more systemic changes to the maternal immune system: There is 
evidence that the maternal immune system generally is skewed towards a Th2 response[30], 
which is characterized by antibody production and inhibition of phagocytic cell 
functions[31], has an anti-inflammatory phenotype with a constant decreased pro-
inflammatory cytokine expression (reduced CCL2, CXCL10, IL-18 and TNF-α), and 
increased anti-inflammatory expression with gestational age[32], and that there is an 
increased amount of T-regs (CD4+FOXP3+) during pregnancy[30, 33, 34], although their 
exact role is uncertain[35]. How these immunological changes and the presence of fetal 
microchimerism affects the mother’s immune system later in life, and in subsequent 
pregnancies, is unknown, but possibly it can reinforce fetal tolerance in future 
pregnancies[36].  
To summarize, multiple, tightly regulated mechanisms are at play to secure a successful 
pregnancy. Breach of tolerance may however occur, and maternal alloimmunization against 
fetal antigens can lead to a condition such as FNAIT.  
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Figure 3: Possible Mechanisms of Fetal Tolerance. Anchoring villous trophoblasts attach to the decidua of 
the uterus and further differentiate into syncytiotrophoblasts, cytotrophoblasts and extravillous 
cytotrophoblasts (EVTs). Floating villous trophoblast, bathed in maternal blood, carry fetal blood vessels and 
can shed placental exosomes, microparticles and fetal cells. Decidual NK cells, induced by IL-15 and SCF 
from dHSCs, promote IDO production and induction of tolerogenic DCs. tDCs, monocytes, and dNKs 
promote T-regs generation and effector T-cell apoptosis. Pregnancy hormones modulate the decidualization. 
DSC=Decidual stromal cell. dHSC=Decidual hematopoietic stem cells. tDC=Tolerogenic dendritic cells. 
SCF=Stem cell factor. MIC-1=Macrophage inhibitory cytokine-1. hCG=Human chorionic gonadotropin. 
KYN=kynurenine. VEGF=vascular endothelial growth factor. Adapted from [37].  
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2 RECENT PATHOPHYSIOLOGICAL ASPECTS OF FNAIT 
 
2.1 THE HPA-1a EPITOPE IS EXPRESSED ON THE PLATELET αIIbβ3 
INTEGRIN 
The HPA-1a epitope is situated on the glycoprotein (GP) IIIa (β3 integrin, CD61), which in 
complex with GPIIb constitutes the fibrinogen receptor on platelets (GPIIb/IIIa, αIIbβ3 
integrin). The HPA-1a epitope is the result of a single amino acid substitution, from proline 
(HPA-1b), to leucine (HPA-1a)[38]. HPA-1a is also expressed on microparticles derived 
from platelets[39]. The fetal platelets express this HPA-1a epitope at least as early as 18 
weeks of gestation[40], and exposure of the epitope by mixing of maternal and fetal blood 
may occur in a fetomaternal bleeding during pregnancy or in conjunction with delivery. 
Nearly all pregnancies have some degree of fetomaternal hemorrhage, but rarely larger 
volumes[41], and the small number of neonatal platelets could be too low to cause an 
maternal alloimmunization[42]. FNAIT may also occur in the first pregnancy. This could 
imply that the HPA-1a epitope is extremely immunogenic, and/or that other sources of the 
epitope than fetal platelets could be involved.  
 
2.2 OTHER SOURCES OF ANTIGEN EXPOSURE – HPA-1a EPITOPE ON 
INTEGRIN αVβ3  
The β3 integrin also forms a heterodimer with the αv integrin (CD51), to form the vitronectin 
receptor αvβ3. The expression of αIIbβ3 on platelets is at least 40-fold higher compared to 
αvβ3[43-45]. However, the αvβ3 complex is in addition to platelets, also expressed on 
placental syncytiotrophoblasts[46], and syncytiotrophoblast particles[47], which may enter 
maternal circulation during pregnancy[48], and hence represents another source of maternal 
exposure to the HPA-1a epitope.  
The αvβ3 integrin complex is further expressed in endothelial cells, where it is involved in 
vasculogenesis[49] and angiogenesis[50]; in a study from 2009, antibodies targeting β3, both 
mouse anti-human CD61 monoclonal antibody, and purified patient-derived anti-HPA-1a 
IgGs, were shown to negatively affect endothelial cell layer spreading and integrity, 
indicating that defective vasculature could contribute to the bleedings seen in cases of 
FNAIT[51].  
The binding of maternal antibodies to HPA-1a on β3 expressed on trophoblast has also been 
suggested to negatively affect trophoblast function: By using a human monoclonal anti-HPA-
1a antibody (26-4) on a first trimester extravillous trophoblast cell line, adhesion and 
migration was reduced by 20%, while there was an inconsistent effect on invasiveness 
(reduced in 3/4 experiments, with 9-25%)[52]. Though with limited demonstrable in vitro 
effects, a reduced trophoblast function in the presence of anti-HPA-1a could theoretically be 
one explanation to the reduced birth weight observed in boys suffering from FNAIT[53], and 
the associated placental inflammation shown in cases of FNAIT[54, 55], but likely other 
mechanisms are also involved (see chapter 2.9.1.).  
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2.2.1 Lessons From Clinical Studies on Anti- αvβ3 and ICH 
Antibodies from HPA-1a immunized mothers are likely to bind both variations of the β3 
integrin (αIIbβ3 and αvβ3), and this has been demonstrated by surface plasmon resonance 
(SPR) technique using a monoclonal antibody derived from an HPA-1a immunized mother 
(26-4)[56]. Few clinical studies have tested for these αvβ3 antibodies until recently: In a 
cohort of FNAIT cases with and without ICH (n=18 per cohort), anti-HPA-1a antibodies 
reactive against αvβ3 from endothelial cells were only detected in the cases with ICH (in 
17/18), and only HPA-1a antibodies of the αvβ3 type (and not anti-β3 type) disrupted 
adhesion to vitronectin, induced endothelial cell apoptosis (anoikis), and disturbed the 
endothelial cell proliferation (tube formation)[57]. This discrimination of subtype anti-HPA-
1a antibodies into anti-αIIbβ3, anti-β3, anti-αvβ3, and associating them to clinical outcome is 
new, and has major implications for the understanding of the pathophysiology of bleedings in 
FNAIT. Testing for anti-αvβ3 could potentially be used to select pregnancies of high risk of 
ICH. How common these types of anti-HPA-1a antibodies are in an unselected (screened 
positive) population is not known, but likely this will be further investigated in larger 
materials in the future.   
FNAIT is often thought of as the platelet equivalent to red cell alloimmunization during 
pregnancy, which causes hemolytic disease of the fetus and newborn (HDFN), and the two 
are often compared. The HPA-1a antibodies in FNAIT are not actually platelet specific, and 
have additional effects other than mediation of platelet destruction; they could also be the 
result of “trophoblast immunization”, and cause bleedings by affecting the function of 
vascular endothelial cells and the angiogenesis during fetal development. This suggests that 
FNAIT could be more different from HDFN than previously assumed, and opens up for a 
new understanding of the pathophysiological processes behind FNAIT. Furthermore, the 
presence of anti-αvβ3 antibodies in FNAIT, and not in maternal idiopathic thrombocytopenic 
purpura (ITP), could perhaps partly explain the lower frequency of ICH associated with this 
condition[58]. 
 
2.3 RECOGNITION OF THE HPA-1a ANTIGEN IS MHC CLASS II RESTRICTED  
Generally, an efficient production of antibodies requires activation of antigen specific B- and 
T lymphocytes (see Figure 2). Perhaps surprisingly, little is known about these cellular 
interactions towards fetal antigens, and how they play a role in the pathophysiology of 
FNAIT. The HLA class II complexes are necessary for presentation of extracellular antigens, 
and overrepresentation of certain HLA class II alleles in immunized mothers has been 
described. About 10% of mothers that are HPA-1a negative (HPA-1bb) are immunized, and 
the majority of immunized mothers are positive for the HLA-DRB3∗0101 allele[8]. The 
HLA-DRB3∗0101 allele together with HLA-DRA, encodes the MHC class II molecule HLA-
DR52a[59], which has been shown to bind β3 integrin from HPA-1a, but not HPA-1b alleles. 
It has been hypothesized that the switch from proline (HPA-1b) to leucine (HPA-1a) 
stabilizes the binding of the antigen to the peptide-binding groove of HLA-DR52a[60]. This 
subsequent increase in affinity leads to an anchoring of a peptide that otherwise would not 
bind, and could explain why immunization towards HPA-1b is so rare (so called 
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unidirectional alloantibody response)[61]. However, production of the so-called low-avidity 
anti-HPA-1a antibodies, which may be detected by SPR, is not associated with HLA 
DRBR3*0101. Mouse studies suggest that these antibodies do not necessarily mediate 
thrombocytopenia, but that they can still cause FNAIT with moderate to severe 
thrombocytopenia in some cases[66]. 
 
2.4 MATERNAL IMMUNE CELLS REACT TO THE HPA-1a ANTIGEN 
Maternal CD4+ T-cells reactive towards allogeneic HPA-1a have been studied: One study 
used HPA-1a peptides with different truncations and substitutions to investigate the specific 
residues required for T cell activation, confirming the previous molecular modeling of the 
binding of HPA-1a to HLA-DR52a [62]. Another study [63] showed that HPA-1a specific 
clonal T cells only proliferated when stimulated by HLA-DRB3∗0101-positive APCs 
presenting the L33 peptide, demonstrating HLA-DR52a restricted recognition of the HPA-1a 
antigen. One role of these T cells is probably to support B cells in antibody production. It is 
known from clinical experience that antibodies can persist in maternal circulation long after 
an HPA-1a incompatible pregnancy; one can therefore assume that there also are long-lived 
plasma cells specific to the HPA-1a antigen. However, there are (to my knowledge) no 
studies on B cell function and FNAIT. 
 
2.5 ANTI-HPA ANTIBODY SPECIFICITIES INVOLVED IN FNAIT  
As mentioned earlier, in Caucasians most cases of FNAIT are due to anti-HPA-1a antibodies. 
Nevertheless, platelets express over thirty different HPAs, and other anti-HPA antibodies can 
also cause FNAIT. The different HPAs are numbered after their discovery, and the high 
frequency alleles are denoted “a”, while the lower frequency alleles are denoted “b”. Besides 
anti-HPA-1a (68%), anti-HPA-1b (6%), anti-HPA-3a (1.3%), anti-HPA-5b (15%), and anti-
HPA-5a (2%) antibodies are the most common antibodies implicated in FNAIT in 
Caucasians[64]. In addition to the well-known anti-HPA antibodies, new low frequency 
platelet antigens are continuously discovered to cause FNAIT[65, 66].  
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Figure 4: Overview of the major human platelet antigens (HPAs) on various glycoproteins (GP), implicated 
in FNAIT. Adapted from[67].  
 
2.6 ANTI-HLA CLASS I ANTIBODIES IMPLICATED IN FNAIT 
A different group of antibodies that is associated with FNAIT is anti-HLA class I antibodies. 
Whether these antibodies actually cause FNAIT, or if they are just an incidental finding, is 
still being debated. HLA class I antigens are present on extravillous trophoblast cells (HLA-
G, HLA-C[68]), and on platelets and nucleated cells (HLA-A, -B, and -C). Platelets, EVTs, 
and other cells or cell particles may be shed into maternal circulation across the placenta 
during pregnancy, in conjunction with delivery, or by a fetomaternal hemorrhage. Maternal 
exposure to fetal HLA class I antigens is therefore likely, and anti-HLA class I antibodies are 
detected in 10-46% of women with a history of pregnancy, depending on detection 
technique[69-74]. As platelets are in abundance compared to other cells, they represent a 
major source of HLA class I antigen in blood[75, 76], and they may be susceptible to binding 
of anti-HLA class I antibodies. In suspected cases of FNAIT, anti-HLA class I antibodies are 
often the only detectable antibody.  
Several case reports on FNAIT due to HLA class I antibodies exist[77-80], but most of these 
do not sufficiently rule out rare and difficult to detect anti-HPA antibodies. In addition, anti-
HLA class I antibodies can often be detected together with anti-HPA antibodies. Possibly 
they could have a synergistic role in causing thrombocytopenia[81], but this has to date not 
been investigated in larger, prospective materials. The presence of anti-HLA class I 
antibodies could also render the treatment of FNAIT due to anti-HPA antibodies less efficient 
because of reactivity against donor platelets[82].  
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To make a diagnosis of FNAIT caused by HLA class I antibodies, other reasons for 
thrombocytopenia need to be ruled out. With a frequency of ca. 1% in unselected 
newborns[83], and in approximately 22% of those admitted to neonatal intensive care 
units[84], neonatal thrombocytopenia is not uncommon. Other potential causes of 
thrombocytopenia include infections, placental insufficiency, asphyxia, aneuploidy, and other 
congenital disorders[85] (examples are listed in Figure 5). However, anti-HLA class I 
antibodies have been suggested to be a cause of thrombocytopenia in small for gestational 
age infants[86], and is associated with a reduced chance for live birth after secondary 
miscarriage[87]. Prospective studies[73], reviews[88], and meta-analyses[89] on anti-HLA 
class I antibodies and FNAIT (or pregnancy outcome[89]) have been inconclusive or 
negative. Anti-HLA class I antibodies can play a role in platelet transfusion 
refractoriness[90], transfusion-related acute lung injury (TRALI)[91], and organ 
transplantations[92]. It is therefore a conundrum that these antibodies can be harmful in other 
settings, but how and if they affect the fetus is still unknown; this warrants further studies on 
anti-HLA class I alloimmunization during pregnancy.  
 
 
Figure 5: Directed Acyclic Graph (DAG) over possible mechanisms behind maternal HLA class I 
alloimmunization and neonatal thrombocytopenia. Created using www.dagitty.net 
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2.7 ANTIBODY COMPOSITION AND PLACENTAL TRANSPORT 
There are different antibody specificities, and there are also different antibody isotypes and 
compositions. Antibodies involved in FNAIT are of the IgG isotype, the main isotype to cross 
the placenta. Concentrations of maternal IgG have been shown to rise from early in the 2nd 
trimester to term, where fetal IgG may exceed maternal levels[93]. The different isotypes 
have different transport capacity, with mostly IgG1 being transported, followed by 
IgG4>IgG3>IgG2[94]. The transport of IgG is an active process mediated by the neonatal Fc 
receptor (FcRn)[95], and is still not completely understood[96].  
 
Figure 6: Basic structure of an immunoglobulin. The unit consists of two identical light chains (L) and heavy 
chains (H), where each region is composed of variable (V) and constant (C) regions. Disulfide bonds maintain 
folding of the protein, and allow for flexibility for better antigen binding. Adapted from [97]. 
 
2.7.1 IgG1 and IgG3 Are the Dominating Isotypes in FNAIT 
In an earlier study on IgGs involved in FNAIT, most maternal sera contained IgG1 alone 
(22/40), or in combination with IgG3 (10/40), while IgG4 was rare (3/40, together with IgG1 
and IgG3) and IgG2 absent[98]. The study included alloimmunized mothers with and without 
thrombocytopenic children (n=36 and n=4, respectively), and there was no association 
between outcome and IgG isotype.  
 
2.7.2 Transport of IgG Across the Placenta 
No large studies have quantified in what extent anti-HPA antibodies are transported across 
the placenta and into the fetal circulation during pregnancy. Though it is possible to quantify 
anti-HPA-1a antibodies[99], fetal sampling during pregnancy is rarely performed due to risk 
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of complications, and sampling from thrombocytopenic neonates could also be problematic. 
One interesting report with regards to the transport of IgG in FNAIT concerns 
polymorphisms within IgG3[100]: Due to an amino acid difference (arginine for histidine), 
IgG3 usually has a shorter half-life compared to the other isotypes (7 days vs. 21 days), 
because of decreased binding to the FcRn, which protects the immunoglobulin from being 
degraded. However, rare allotypes of IgG3 (with the histidine substitution) can bind the FcRn 
with higher affinity, so that the half-life is at a level similar to IgG1[101], and it was shown 
that this IgG3 allotype could be transported across the placenta as efficiently as IgG1[100]. 
Higher levels of IgG3 in the neonate could be clinically relevant as IgG3 is thought to have a 
high capacity to bind FcRs and activate effector functions, especially FcγRIIIA (on 
macrophages, NK cells, and monocytes)[102]; though rare, the presence of this IgG3 allotype 
could potentially explain some of the heterogeneity in outcome of pregnancies with FNAIT, 
and there is some evidence towards associations between IgG3 concentrations and severity of 
FNAIT[103]. By comparing concentrations in the mother and neonate (cord blood) directly 
after delivery, the study also showed a correlation between maternal and cord blood total IgG 
levels in normal pregnancies, with a saturation of cord blood IgG concentration that was 
enhanced when the mothers were treated with IVIG[100]; this could be one possible 
mechanism as to why IVIG seems to protect against bleedings[104]. 
 
2.7.3 IgG Composition May Dictate Antibodies’ Effector Functions  
Immunoglobulins are glycoproteins, and lately the glycan composition of IgG1 in FNAIT has 
been more closely described[105, 106]: The Fc part of the IgG, which binds to Fc receptors 
(FcγR), and subsequently plays a large role in orchestrating the antibody effects, may have 
different sugar molecules (glycosylation), which affects this FcγR binding and subsequently 
the activity of antibody effects. These differences in antibody effects could help explain the 
varying association between antibody titer and clinical outcome[107-109]. Indeed, it was 
shown that decreased levels of fucose enhanced in vitro phagocytosis of platelets, and was 
associated with a worse clinical outcome with lower platelet counts and more severe 
bleedings (n=48); however, no sera from cases of ICH were investigated in the study. These 
effects can be explained by an enhanced binding to FcγRs with lower levels of IgG core 
fucosylation. Skewing in fucosylation was only seen for anti-HPA-1a antibodies formed 
during pregnancy; anti-HLA class I antibodies formed during pregnancy and antibodies from 
platelet refractory patients had higher levels of fucosylation[105]. Why such changes in 
fucosylation appear is not known, but it is likely tightly regulated, and could reflect a 
combination of the unique immunological environment during pregnancy and the HPA-1a 
antigen[105]. A later article from the same group demonstrated in a larger cohort of samples 
(n=166), including 26 longitudinal samples, that the glycosylation pattern changed with the 
first pregnancy, and then remained stable in subsequent pregnancies. By using ICH or fetal 
death as outcome in a multivariate model, the authors suggested that a combination of 
fucosylation (decreased levels), galactosylation (increased levels), together with antibody titer 
could be used to identify risk of severe FNAIT[106]. Such a model needs to be validated in 
larger cohorts, and could possibly be of use in future screening for FNAIT. 
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2.8 ANTI-HPA-1a ANTIBODIES MEDIATE PHAGOCYTOSIS IN VITRO 
Without direct in vivo evidence, it has been assumed that the main mechanism behind the 
thrombocytopenia in FNAIT is phagocytosis of platelets; binding of antibody coated platelets 
to Fcγ receptors (FcγR) on mononuclear phagocytes (for instance macrophages in the liver 
and spleen) leads to destruction and removal of platelets from the fetal circulation. In vitro 
experiments have shown that platelets sensitized with anti-HPA-1a antibodies bind FcγRI 
and FcγRII on neonatal monocytes[110]. The same group later published a study using an in 
vitro platelet phagocytosis assay. Phagocytosis was found to be dependent on serum 
concentrations of anti-HPA-1a antibodies and time, and inhibited by IVIG, a monoclonal 
anti-FcγRI antibody, and cytochalasin D (which binds actin filaments on platelets and 
thereby hinder the engulfment needed for successful phagocytosis). However, two of the six 
anti-HPA-1a sera tested did not induce phagocytosis, despite coming from immunized 
mothers of thrombocytopenic children, which the authors suggest was due to a higher binding 
and phagocytosis potential in in vivo splenic macrophages compared to monocytes used in 
the in vitro assay. Anti-FcγRII antibodies only inhibited phagocytosis mediated by one of the 
two anti-HPA-1a sera tested. Also, anti-FcγRIII antibodies did not inhibit the phagocytosis, 
which was attributed to the expression of this FcγR on only a certain monocyte subset, 
suggesting this FcγR could still mediate phagocytosis in vivo[111]. These results suggest that 
the interplay between anti-HPA-1a and the different Fc-receptors is tightly regulated, and that 
the extent of phagocytosis can vary considerably between individuals. 
 
2.8.1 Phagocytosis Can Be Affected by Neonatal Factors 
A later study confirmed the findings that anti-HPA-1a antibodies could mediate phagocytosis, 
and showed that CRP could enhance this platelet destruction [112]. The study also showed an 
elevated CRP level in neonates diagnosed with FNAIT and children with ITP, compared to 
cord blood of healthy neonates. In a mouse model, high concentrations of CRP and anti-
platelet antibodies lead to a decreased platelet count compared to antibodies alone, whereas 
CRP alone had no effect. This suggests that CRP can enhance phagocytosis mediated by anti-
HPA-1a antibodies. As an elevated CRP can be present in neonates for many different 
reasons (including non-infectious causes such as a prolonged delivery[113]), this could be 
clinically relevant for FNAIT.   
 
2.9 OTHER POTENTIAL MECHANISMS INVOLVED IN FNAIT 
2.9.1 NK Cells 
There are other mechanisms than phagocytosis of platelets that can cause thrombocytopenia 
and bleedings in FNAIT. Firstly, other mechanisms of antibody-mediated platelet destruction 
have not been thoroughly investigated in FNAIT, and it cannot be ruled out that for instance 
antibody-dependent cell-mediated cytotoxicity (ADCC) through NK cells (which usually 
express FcγRIII) is involved. ADCC is an important mechanism of hemolytic disease of the 
newborn, and in an earlier study ADCC lysis was shown to correlate with anti-A/B IgG3 
titers, number of A/B antigen per red cell, and clinical severity of the newborn[114]. It is not 
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unlikely that NK cells can also kill anti-HPA-1a sensitized platelets, and the degree to which 
it contributes to the thrombocytopenia in FNAIT has not been investigated.  
A recent study demonstrated another possible role of NK cells in FNAIT: Using a murine 
model of FNAIT, uterine NK cells were implicated in fetal loss and growth restriction[115]. 
The authors hypothesized that maternal anti-β3 IgG antibodies binding to fetal alloantigen 
expressed on trophoblast could trigger ADCC and subsequently trophoblast cell death, 
ultimately leading to pregnancy failure. Immunized mice had splenomegaly with pro-
inflammatory Th17 cells, increased plasma levels of pro-inflammatory cytokines, and a 
skewed profile of pro- and anti-angiogenic factors. The fetuses had impaired placental 
exchange functions, and the majority died mid gestation. Decidual numbers of uNK cells 
were increased, with higher perforin and NKp46 expression, and increased degranulation 
(CD107+ NK cells), suggestive of cytotoxicity. Interestingly, treatment with anti-NK 
antibodies reduced number of miscarriages and protected against the placental changes.  
There are several drawbacks to the use of this study model (also discussed in chapter 2.9.4). 
Notably, the mice were only immunized after transfusion of wild type (WT) platelets, not 
after the first or second pregnancy after breeding with a WT mouse, which was used as 
control. This is in contrast to a human setting, where immunization after transfusion of HPA-
1a positive platelets is rare[116]. Immunization after transfusion can differ from that after 
pregnancy, considering the different immunological environments. However, this study 
highlights intrauterine growth restriction as an important aspect of FNAIT, and could pave 
the way for further studies on human materials. Furthermore, it demonstrates that NK cell 
mediated ADCC indeed could be implicated in FNAIT, which possibly opens up for new 
treatment strategies. 
 
2.9.2 Immune Destruction of Platelets May Be Independent of B-cells  
Although it might be a stretch to compare with FNAIT, destruction of platelets in platelet 
refractoriness was recently shown to be antibody and B-cell independent, and rather mediated 
by CD8+ T cells in mice[117]: Platelet refractoriness is defined by the lack of an increment in 
platelet counts after transfusion, and although it occurs in patients without anti-HLA class I 
antibodies (and vice versa), efforts are going into matching donor and recipient platelets by 
their HLA class I expression to treat refractory patients. The study immunized mice with 
mismatched MHC antigens, and found that B cell deficient mice cleared transfused MHC 
mismatched platelets, and that depletion of CD8+ T cells in vivo improved the survival of 
mismatched platelets. This could have implications for the treatment of platelet refractoriness, 
which often focuses on the antibody component, and perhaps could also be a mechanism 
behind platelet clearance in FNAIT[118]. Although in many ways a different condition, 
another hint towards the potential role of cytotoxic T cells in FNAIT comes from idiopathic 
thrombocytopenic purpura (ITP), where CD8+ T cells have been shown to be involved 
through different mechanisms[119, 120]. How and if maternal CD8+ T cells could lead to 
destruction of fetal platelets is an open question, but maternal CD8+ T cells can cause 
placental villitis[121], which can be found in cases of FNAIT[55] (described in chapter 2.12). 
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2.9.3 Anti-HPA-1a Antibodies Can Negatively Affect Megakaryocytes 
Going back to effects mediated by anti-HPA-1a antibodies, both increased platelet 
destruction and reduced platelet production could lead to a low platelet count: 
Megakaryocytes (MKs) are bone marrow progenitors of platelets, regulated by 
thrombopoietin (TPO) in a homeostatic manner[122, 123], and also express the HPA-1a 
antigen. In a cell culture model, 14/17 selected anti-HPA-1a sera from FNAIT cases was 
shown to reduce megakaryopoiesis, and induced apoptosis and cell death of early 
megakaryocytes (progenitors), while the surviving MKs had a normal maturation. The MK 
growth in culture correlated with neonatal platelet counts from women undergoing IVIG 
therapy during pregnancy, and the authors even suggested this to be a potential predictive 
factor for the effect of maternal IVIG therapy[124]. It is an interesting notion that anti-HPA-
1a antibody suppression of MKs could have an additive effect on decreased platelet counts, 
possibly limiting the body’s normal response to an increased demand for platelets. 
 
2.9.4 Blocking of the β3 Integrin and Bleedings – Differences in Mice and Men 
There’s not always a strict correlation between platelet counts and the severity of the bleeding 
in cases of FNAIT, suggesting a low platelet count alone is not the sole reason for these 
bleedings. This has recently been elucidated by two studies: The first is based on a mouse 
model where platelet antigen (β3 or GPIbα) deficient mice were immunized by transfusing 
wild type platelets, and then bred with wild type mice. It was shown that, although giving 
similar levels of thrombocytopenia, only anti-β3 sera and not anti-GPIbα sera negatively 
affected angiogenesis and induced ICH in the pups. The impaired angiogenesis could be 
rescued by IVIG[125]. A drawback in this study is that the immunization after platelet 
transfusion and during pregnancy might differ: There will be no exposure of the antigen in 
the placenta when immunizing with platelets, and the immune response to antigen may differ 
during pregnancy. Also, the β3 deficient mice were shown to have placental defects and 
postnatal hemorrhages in the first paper introducing the mouse model, originally developed to 
study Glanzmann thrombasthenia[126], suggesting that the absence of the β3 integrin itself 
could also negatively affect the neonatal outcome, even without alloimmunization. More 
importantly, anti-β3 antibodies may have different effects than anti-HPA-1a antibodies, in 
that the binding sites and subsequent potential to block the β3 integrin would be different. 
Further, the mice were injected with anti-β3 sera, which may contain several different types 
of anti-β3 antibodies. However, following this study came the work on anti-αvβ3 antibodies 
from cases of FNAIT with ICH previously mentioned[57], demonstrating the clinical 
relevance of these striking mouse model findings. Although contrasting to the mouse study, 
anti-β3 antibodies did not negatively affect human endothelial cells (only anti-αvβ3 
antibodies had this effect). Together, these studies suggest that negative effects on endothelial 
cells, and subsequent vascular impairment, likely play an important role for bleedings in 
FNAIT. 
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2.9.5 Effects of Anti-HPA-1a Antibodies on Platelet Function 
Platelets are essential for successful coagulation, which can be summarized in three 
overlapping stages: Initiation, where platelets bind vWF, collagen or tissue factor exposed on 
a cell surface; amplification, with activation of platelets and co-factors; and propagation, 
where large amounts of thrombin are generated on the activated platelet surface[127]. It has 
been hypothesized that another possible explanation for the occasional dissociation between 
neonatal platelet counts and presence of severe bleedings in FNAIT could be the antibodies’ 
effect on platelet function, as the anti-HPA-1a alloantibodies target their epitope on the 
fibrinogen receptor - an important functional platelet glycoprotein.  
 
 
Figure 7: Simplified overview of platelet activation and thrombus formation. After adhesion to a von 
Willebrand factor/collagen matrix, platelets are activated, and secrete granular contents; platelets further 
aggregate via integrins, produce thrombin after developing a pro-coagulant (phosphatidylserine (PS)-
exposing) surface, and with fibrin threads make up a contracted thrombus. Formed thrombin again activates 
platelets via G-protein coupled receptors (GPCR), to further activate coagulation factors, and convert 
fibrinogen to fibrin. The color codes reflect a low (green) to high (red) Ca2+ signal. Adapted from [128]. 
 
2.9.6 Fibrinogen Binding and Platelet Activation 
Fibrinogen is a large molecule with multiple interaction sites that can bind to several 
receptors, and among these, integrin αIIbβ3[129] and αvβ3[130] are the best characterized. 
Apart from its role in maintaining hemostasis by mediating platelet aggregation, clot 
formation, and wound healing, it can, together with fibrin, also function as a component of 
extracellular matrix in other processes, supporting placental development, angiogenesis, 
atherosclerosis, and metastasis[131]. 
On resting platelets, only immobilized fibrinogen binds to the GPIIb/IIIa, but upon activation 
induced by ADP, thrombin, or collagen, an active conformation of the receptor will allow for 
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increased binding of fibrinogen. Fibrinogen binds to the active GPIIb/IIIa with a dissociation 
constant (Kd) of 100 nM, 100 times lower than the concentration of fibrinogen in plasma, 
which suggests immediate binding to the receptors – the binding activity of GPIIb/IIIa 
therefore needs to be tightly regulated[132].  
On the integrin αIIbβ3, fibrinogen has two binding sites, and two signaling events act in 
synergy to activate the platelet and promote cell spreading to surface-bound fibrinogen [131]: 
An initial binding to the αIIb subunit generates signaling events that lead to clustering of 
αIIbβ3 in focal complexes, as well as intracellular signals (FAK tyrosine phosphorylation 
and Rac1 activation). The second signaling event is the binding of fibrinogen to β3 (RGD-β3 
interaction), which relies on receptor activation. Conformational changes following this 
interaction allows for a second wave of intracellular signals (such as RhoA activation, which 
is required for cell spreading). 
In addition to cell spreading, fibrinogen binding initiates outside-in signaling that ultimately 
leads to activation of the platelet with the release of granules (Figure 8). These granules 
contain adhesion proteins, nucleotides, and enzymes (such as ADP, ATP, vWF, fibrinogen, 
coagulation factors, cytokines, serotonin, histamine) in different compositions, depending on 
granule type. The release of these mediators will together with platelet-platelet interactions 
amplify the activation of the platelets, recruit circulating platelets into aggregates, and 
stabilize the thrombus[133].  
Considering the distal location of the HPA-1a epitope in relation to the fibrinogen binding 
site on GPIIIa[134], any inhibitory effect on platelet function could likely result from a form 
of allosteric hindrance of fibrinogen binding. Decreased fibrinogen binding could decrease 
the release of granules, which can be reflected by decreased CD62-P expression, and interfere 
with platelet-platelet interaction, which can be reflected by decreased aggregation. Such 
effects have been evaluated in a handful of studies, described below. 
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Figure 8: Signaling pathways of three major platelet receptors. Activation of αIIbβ3 leads to binding of 
fibrinogen, which may initiate an outside-in signaling that ultimately leads platelet activation and granule 
secretion. Adapted from[133]. 
 
2.9.6.1 Functional Effects of Recombinant Anti-HPA-1a Antibodies 
In a study from 2004, effects of a recombinant human IgG1 anti-HPA-1a antibody (B2GI), 
designed as a potential therapy for FNAIT, were tested on adult platelets using several 
assays[135]: For HPA-1ab platelets, the antibody decreased aggregation measured by the 
PAP-4 aggregometer (which measures alterations in light transmission) with ADP as stimulus 
(and not collagen) by 50%, and in a whole blood perfusion assay, platelet adhesion to slips 
covered with fibrinogen was inhibited by about 20% (again, no effect on collagen-coated 
surface). Closure time was not affected for HPA-1ab platelets, while HPA-1aa platelets were 
inhibited. In a whole blood flow perfusion assay, αvβ3- and αIIbβ3-mediated cell adhesion 
to fibrinogen was also measured, using transfected chinese hamster ovary (CHO) cells: 
αIIbβ3-Leu33 or αvβ3-Pro33-mediated cell spreading was not affected by pre-incubation 
with the antibody, but the antibody affected αβ3-Leu33 (HPA-1a) mediated cell spreading 
and attachment. 
In summary, while the study showed pronounced effects on HPA-1aa platelets in some of the 
assays, few and mild effects were demonstrated on HPA-1ab platelets, and the most 
pronounced effects was for aggregation with a weak stimulus (ADP), and for assays testing 
fibrinogen binding to platelets. Although this study thoroughly investigated antibody effects 
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on platelet function (and possibly also laid some of the foundation for the later anti-αvβ3 
discoveries), it is limited by the use of adult platelets only, and recombinant antibodies may 
have different effects than (polyclonal) alloantibodies in vivo. 
 
2.9.6.2 Human Anti-HPA-1a Antibodies 
Another study, where the primary aim was to produce a human monoclonal anti-HPA-1a, 
also described inhibitory effects on platelet aggregation[56]. The investigators incubated 
adult whole blood anti-coagulated with hirudin with the antibody, and measured aggregation 
using the Multiplate (which measures changes in electrical resistance with aggregation of 
platelets). HPA-1ab platelet aggregation was reduced 20% compared to the control (no 
antibody).  
In a study from 1994[136], binding of radiolabelled fibrinogen to washed and stimulated 
adult HPA-1aa platelets was investigated in the presence of sera from mothers of children 
with FNAIT, and patients with post transfusion purpura (PTP), both containing anti-HPA-1a 
antibodies. Surprisingly, while 6/7 PTP sera inhibited fibrinogen binding, none of the nine 
maternal sera affected fibrinogen binding. The use of sera and not purified IgG may have 
affected the results, and anti-HPA-1a titers were low for the FNAIT sera.  
In an interesting study from 1984[137], plasma from two immunized mothers were used to 
investigate effects on platelet function. Effects of plasma, isolated anti-HPA-1a IgG, and the 
epitope-binding F(ab) and F(ab’)2 fragments of IgG were investigated. Aggregation, 
measured by changes in light transmission, was inhibited in a dose-dependent manner by 
plasma when induced by ADP and collagen, but not by ristocetin (a more potent stimulus 
compared to ADP and collagen), while change in platelet-shape with stimulation was 
observed to be normal. Anti-HPA-1a plasma also inhibited ADP-induced clot retraction. 
Interestingly, binding of radiolabelled fibrinogen was reduced down to similar levels as 
patients with Glanzmann’s thrombasthenia (GT), who lack an effective fibrinogen receptor. 
The authors suggested that indeed these anti-HPA-1a antibodies could induce a similar 
platelet phenotype as in GT patients, and could ascribe these changes to the epitope binding 
of anti-HPA-1a antibodies by using F(ab) and F(ab’)2 fragments of IgG. The authors reported 
similar effects on HPA-1a heterozygous and homozygous donors. One of the major findings 
of the study at the time was actually the association of HPA-1a antibody binding to the 
fibrinogen-binding site, which suggested that fibrinogen bound to the GPIIIa.  
Since we now can assume that there are different types of anti-HPA-1a antibodies, this could 
perhaps also explain some of the heterogeneity in studies examining the effect of these 
antibodies using maternal sera. In a study from 2005, sera from FNAIT cases (n=43) and PTP 
cases (n=8) were used to examine inhibition of cell adhesion to fibrinogen[138]. Of the 
FNAIT sera, only two specifically inhibited HPA-1a cells. In both of these cases the children 
had severe bleedings, but this also occurred in sera without inhibitory effects. Also, two other 
sera blocked both HPA-1a and HPA-1b cells. The authors suggested that these different 
effects could be the result of alloantibody maturation, starting from unspecific inhibition to 
allospecific inhibition, and finally to no inhibitory capacity, and that the timing of sampling 
could explain the low number of inhibitory alloantibodies. It is difficult to know whether such 
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maturation would follow this pattern with regards to inhibitory capacity or not; the HPA-1a 
epitope is distal to the fibrinogen binding site[134], but possibly there can still be a form of 
allosteric hindrance with the increased binding affinity of “matured” anti-HPA-1a antibodies. 
Moreover, differences in the composition of polyclonal anti-HPA-1a antibodies in the sera 
could possibly affect the level of this allosteric hindrance.  
It is evident from these studies that anti-HPA-1a antibody likely can affect platelet function, 
and that a monoclonal anti-HPA-1a antibody (or antigen-binding fragments of such 
antibodies) is most suitable for further mechanistic studies of these effects, although this 
approach is more difficult to translate into the in vivo setting. 
 
2.9.6.3 Activating Effects of Anti-HPA-1a Antibodies 
Platelet antibodies may also have activating effects, by clustering and cross-linking of Fc 
receptors (demonstrated for anti-GPIb moAbs[139]), antibody-mediated complement 
activation [140], or direct binding to and triggering of a signal-transducing antigen. However, 
few studies on this are performed, and the antibody effects have shown great heterogeneity, 
possibly due to differences in platelet activation, and presence of other antibodies (such as 
anti-HLA class I antibodies) in the sera [141]. In a study from 2001, anti-HPA-1a sera from 
immunized mothers and PTP patients were incubated with HPA-1aa platelets, and the release 
of RANTES (regulated on activation, normal, T-cell expressed, and presumably 
secreted/CCL5 – a chemotactic) measured; only two out of eleven FNAIT sera induced 
release of RANTES in HPA-1aa platelets, which could be blocked by anti-FcγRII 
antibody[142]. Only HPA-1aa and HPA-1bb platelets were tested in the study, so the 
relevance to FNAIT is difficult to ascertain, but theoretically this effect could be present in a 
lesser degree in FNAIT. 
 
2.10 NEONATAL HEMOSTASIS  
Another important aspect in FNAIT is the neonatal platelet function itself, which may differ 
from adults, and render them more vulnerable for potential antibody effects. Newborn 
hemostasis is thought to evolve with gestational age, so called “developmental hemostasis”: 
Concentrations of coagulation factors and proteins increase during pregnancy, and while 
levels of vitamin K-dependent factors (II, VII, IX, X), contact-dependent factors (XI, XII), 
and thrombin are lower than adult values, neonates also have lower levels of inhibitors of 
coagulation and fibrinolysis, which ensures hemostatic balance[143]. With higher levels of 
hematocrit, presence of large nucleated red cells and increased levels and function of von 
Willebrand factor (vWF), primary hemostasis is thought to be enhanced in neonates [143, 
144]. 
 
2.11 NEONATAL PLATELET FUNCTION  
As opposed to quantifying coagulation factors, functional studies of platelet function require 
relatively large volumes of blood, and so there are a limited number of such studies on 
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neonatal platelet function. However, when using flow cytometry very small amounts of blood 
are needed, and in a study from 2009, in vitro reactivity of neonatal platelets was shown to be 
decreased compared to adults: Neonatal platelets had a lower expression of CD62-P (P-
selectin, released from α-granules upon stimulation) and PAC-1 (activated GPIIb/IIIa) after 
stimulation with thrombin receptor activating peptide (TRAP). Neonatal platelets had a 
higher CD62-P and a lower PAC-1 expression on resting platelets. They also had a lower 
GPIIb/IIIa (CD41), GPIIIa (CD61), and GPIb (CD42a) expression, and these tendencies were 
more pronounced with lower gestational age. In term neonates, the expression of CD62-P in 
response to TRAP increased during 12 days after delivery (from less than 20% to ca. 50% 
positive platelets)[145].  
Another type of more functional studies is platelet function tests such as platelet function 
analyzer (PFA-100), cone platelet analyzer (CPA) and rotating thromboelastogram 
(ROTEM). Neonatal (n=17) blood has been shown to give a shorter closure time than adults 
(n=31) with the PFA-100[146], while platelet function measured by CPA was shown to 
correlate with gestational age (total n=231)[147]. Recently neonatal reference ranges for 
ROTEM were established, and using cord blood from 184 term and 47 pre-term neonates, 
clotting time (CT) and maximum clot firmness (MCF) was found to be lower in neonates 
compared to adult reference values[148]. 
To summarize, although there is a limited number of studies, it appears that neonatal platelet 
function in vitro is reduced compared to adults, and that compensatory mechanisms such as 
enhanced primary hemostasis could explain why newborns normally don’t have an increased 
bleeding tendency. However, this balance could be vulnerable, and may perhaps be affected 
by conditions such as FNAIT, where anti-HPA-1a antibodies may interfere with hemostasis. 
 
2.12  CLINICAL MANIFESTATIONS OF FNAIT 
In the absence of screening programs, most cases of FNAIT are diagnosed when a newborn 
presents with petechiae or other signs of bleedings. In addition to thrombocytopenia and 
potentially severe bleedings, presence of anti-HPA-1a antibody has been shown to be 
associated with fetal growth restriction in boys [53], which also could give long-term 
consequences for the child[149]. FNAIT is also likely to cause miscarriages and fetal 
loss[150], but it is unknown how often this is caused by FNAIT.  
Smaller, retrospective cohorts of untreated FNAIT have revealed placental findings 
characterized by chronic inflammatory reactions, such as chronic chorioamnionitis and 
villitis[54, 55]. Chronic villitis is associated with IUGR, and suggested to be a mark of breach 
of fetal-maternal tolerance[121, 151]. In light of the recent study on uNK cells mediating 
IUGR in mice suffering from FNAIT [115], such mechanisms should be further addressed in 
a human setting, with larger cohorts of patients. 
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2.12.1 Incidence of Intracranial Hemorrhages Associated with FNAIT 
Intracranial hemorrhage has been considered the most feared complication of FNAIT, as it 
can be life threatening and give lifelong impairment. In contrast to the focus on risk of ICH in 
FNAIT, the true incidence of ICH due to FNAIT is unknown, as most screening studies have 
included interventions to avoid bleedings[7]. A systematic review from 2014 on incidence of 
FNAIT based on prospective screening studies of low-risk unselected newborns, found a 
pooled incidence of ICH due to FNAIT at 6 per 100,000 newborns. In total, almost 60,000 
newborns were screened for thrombocytopenia, and all cases of ICH appeared to have 
occurred in utero[152].  
 
2.12.2 Retrospective Studies on ICH and FNAIT 
The largest study describing cases of FNAIT with ICH to date is based on an international 
multicenter registry, and reviewed all diagnosed cases of FNAIT with ICH over a nine-year 
period[153]. Most of the bleedings occurred early, before 28 weeks of gestation (gw) (23/43, 
54%), and affected the first-born child (27/43, 63%). Where the types of bleedings could be 
described, 15 were classified as intraparenchymal, and 13 as intraventricular/periventricular 
hemorrhage (IVH/PVH). Some cases had multiple bleeding episodes, or a mix of different 
types of bleedings. In the cases with bleedings before 28 gw, all except one were classified as 
IVH/PVH. The bleedings in this study were associated with a severe outcome; only 5 (12%) 
were discharged alive and well, 6 (14%) were stillborn, 9 (21%) died after delivery, and 23 
(53%) were discharged with neurological impairment. The study has the limitation of being a 
retrospective study; without any screening for platelet alloimmunization, neonatal 
thrombocytopenia, or presence of intracranial hemorrhage (which may be 
asymptomatic[154]), only clinically recognized cases are included, and so probably only the 
most severe cases of ICH due to FNAIT were described. The study shows these bleedings 
may occur early in pregnancy, which could be of importance for any future screening and 
intervention program, and could also fit with the development of the fetal brain - perhaps the 
neonates would be more vulnerable for antibodies targeting endothelial cells earlier in 
gestation. The fact that most of the cases were premature, could also point towards 
multifactorial causes of bleeding.  
 
2.12.3 Predictors of ICH 
As maternal platelet alloimmunisation can manifest as anything from a healthy newborn 
without thrombocytopenia, to asymptomatic thrombocytopenia without bleedings, 
symptomatic thrombocytopenia with minor bleedings, and to thrombocytopenia and life-
threatening bleedings, it is important to predict in which cases a severe bleeding such as an 
ICH is more likely. Unfortunately, the strongest predictors for an ICH is number of 
gestations[155] and a previous child with ICH[156]. For primiparous women, antibody levels 
is of limited use[107], but they may together with HLA class II typing help predict a severe 
ICH and response to IVIG therapy[155]. Factors that potentially could be used to predict 
severe FNAIT are summarized in Table 1.  
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Table 1: Potential predictors of severe FNAIT. 
  
Factors That Could Predict Severe 
FNAIT (ICH) 
Comment 
Previous ICH  Important predictor in subsequent pregnancies [155, 156] 
Presence of anti-HPA-1a subtypes 
(anti-αvβ3) 
Probably of great importance, but only 
one clinical study [57] 
Glycosylation pattern 
Strong evidence, but needs to be shown 
in larger, prospective cohorts of cases 
[106] 
Antibody titer Variable effect [107, 109, 157], could be useful in subsequent pregnancies 
HLADRB3*0101 positive mother 
Probably necessary for efficient 
immunization, not useful for predicting 
severity of FNAIT [158, 159] 
Number of gestations Uncertain variable, and not useful in the first pregnancy 
IgG3 polymorphism 
Rare polymorphism, could lead to 
increased exposure of anti-HPA-1a 
antibodies to the fetus 
IVIG response in MK/anti-HPA-1a 
culture Likely not feasible, and uncertain 
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2.13 SUMMARY  
FNAIT is a complex condition. Exposure of the antigen to the maternal immune system and 
its response, the different types of antibodies, and the fetal development and reaction to 
alloantibodies all likely determine the neonatal outcome. Still, central immunological aspects 
remain uncertain, and the potentially severe consequences of FNAIT calls for further 
research.  
 
 
 
Figure 9: Overview of possible mechanisms involved in FNAIT. Created using www.dagitty.net. 
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3 AIMS OF THE THESIS 
The two main aims of the thesis was to use both clinical and experimental data to investigate 
possible underlying mechanisms of FNAIT, and to evaluate the impact of FNAIT on neonatal 
morbidity in Sweden by investigating the frequency of maternal platelet alloantibodies in 
newborns diagnosed with an intracranial hemorrhage (ICH). More specifically, the aims 
were: 
 
• To further describe anti-HLA class I antibody specificities and levels in cases of 
clinically suspected FNAIT, to shed light onto whether anti-HLA class I antibodies 
could cause FNAIT in some cases (paper I and II)  
 
• To describe clinical characteristics of cases of suspected FNAIT where only anti-
HLA class I antibodies are detectable (paper I and II) 
 
• To determine whether certain fetal-maternal mismatches in HLA class I genotype is 
associated with neonatal thrombocytopenia (paper II) 
 
• To investigate the HPA-1a epitope expression on neonatal platelets, and further 
investigate neonatal platelet function with regards to FNAIT (paper III) 
 
• To investigate whether anti-HPA-1a antibody could affect platelet function, and 
generate hypotheses that can inform future studies investigating such effects (paper 
III) 
 
• To investigate the prevalence of platelet alloantibodies in mothers of newborns born 
from 32 weeks of gestation and diagnosed with an ICH in Sweden (paper IV) 
 
• To describe clinical characteristics of neonates diagnosed with an ICH born from 32 
weeks of gestation (paper IV) 
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4 RESULTS AND DISCUSSION STUDY I AND II 
Both study I and II spring from the same underlying research question of whether anti-HLA 
class I antibodies could be a cause of FNAIT. As a means to elucidate this underlying 
question we aimed to describe the antibody response and clinical data associated with cases 
of suspected FNAIT with only HLA class I antibodies detectable. The two studies share 
similarities in approach and case selection, and while the results are mainly in consonance, 
study II also provides a potential resolve to some of the issues from study I.  
 
4.1 SUMMARY OF MAIN FINDINGS STUDY I 
In paper I, the main findings can be briefly summarized as follows: Twenty-three cases from 
260 national referrals for suspected FNAIT from January 2007 to March 2012 were included 
(Fig. 1). The cases had an increased antibody reactivity towards HLA class I antigens 
compared to both control groups – representing that of a normal pregnancy (control mothers, 
n=33), and background levels after previous immunizations (blood donors, n=19). This was 
quantified by comparing the number of HLA class I antigen coated beads with SFI>9999, and 
by comparing median SFI levels for all reactive antigen beads (HLA-ABC SFIs). For cases 
and control mothers, the SFI levels were highest for antibodies targeting HLA-B antigens, 
compared to HLA-A and -C, although only the HLA-A vs. -C comparison reached statistical 
significance. Blood donors had a tendency towards increased reactivity against HLA-C 
antigens. For the particular antibody specificities, only two were more frequent among cases 
(A*03:01 and A*66:02), and reactivity against all antigens were seen in both cases and 
control mothers. Most of the specificities were directed against very rare HLA class I 
antigens. The available clinical data revealed a case population with a high morbidity, and the 
majority of selected cases actually had other factors that could contribute to 
thrombocytopenia. 
 
4.2 SUMMARY OF MAIN FINDINGS STUDY II 
The results from paper II are in many aspects similar to paper I: The cases were based on 
national referrals over an eleven-year period (n=537), and selected on the basis of anti-HLA 
class I antibodies and available clinical data. The final study population consisted of 50 cases 
(Fig. 1). Controls were samples from normal pregnancies (n=60). Similarly to paper I, the 
cases had higher antibody levels compared to controls, as quantified by comparing number of 
specificities with MFI >10 000. Broad reactivity patterns were also apparent in this study 
population, but could be resolved by applying data on HLA class I epitope expression; the 
reactivity proved to be mainly specific against paternally-inherited epitopes, with little 
reactivity against maternal self or third-party antigens (n=33 for genotyping data). As in 
paper I, cases and controls reacted against the same antigen beads, there were no particular 
mismatches that were associated with immunization among the cases. However, with the 
addition of genotyping data, it could be demonstrated that cases with a more severe outcome 
had a tendency towards higher reactivity against paternal antigens, and that multiparous 
mothers had significantly higher MFI levels of paternal-specific antibodies. Comparing to the 
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background population, the case population had similar HLA class I allele frequencies, 
though with a higher frequency of HLA-A*31 and HLA-B*27, which should be interpreted 
with caution considering the disparate sample sizes. The clinical data revealed a population 
with severe thrombocytopenia, and a high frequency of ICH at 10%. Although compared to 
the population described in paper I, this case population apparently had fewer factors that also 
could explain thrombocytopenia, there was a high frequency of caesarean sections (50%), 
preeclampsia (13%) and small for gestational age neonates (48%).  
 
4.3 DISCUSSION   
4.3.1 Increased Reactivity Against HLA-B Antigens 
One of the main findings in both studies is the increased level of antibodies directed against 
HLA-B antigens. In study II, 97% of cases had at least one mismatched HLA-B antigen 
between mother and neonate (likewise, 79% had a HLA-A antigen mismatch). These two 
findings may be explained by the high degree of polymorphism in the HLA-B alleles; to date, 
almost 5,000 alleles have been described (hla.alleles.org, retrieved 17-09-10), which means a 
mismatch between mother and neonates is almost inevitable. Furthermore, there is some 
evidence that HLA-B antigen is expressed earlier than HLA-A on fetal villous stromal cells 
in human placenta, demonstrated by use of immunohistochemistry[68], which could imply 
that immunization against HLA-B may occur earlier, and therefore could give rise to a more 
potent immune response. In both papers, the reactivity against HLA-C antigens were much 
lower than that directed against HLA-A and -B, and in paper II, most of the reactivity against 
HLA-C could be ascribed to epitopes shared with HLA-A and -B antigens. This is in line 
with the low expression of HLA-C antigens on most cells[160], including platelets[161], but 
in contrast to the HLA class I antigen expression in the placenta – where HLA class I is 
mainly expressed as HLA-C, -E, and -G on extravillous trophoblast (EVT)[162]. This implies 
that other cells than EVTs are the likely source of immunization.  
 
4.3.2 Nulliparity 
If EVTs were not the source of immunization, this would indicate that also other cells were 
available to the maternal immune system during pregnancy. Many of the case mothers (9/16 
in paper I, and 21/47 in paper II) were nulliparous – it is therefore likely that the 
immunization against cells other than EVTs occurred during pregnancy, and not due to a 
delivery or a secondary immune response in a subsequent pregnancy. Transfusion and 
transplantation can also lead to HLA class I immunization, but is rare in women of fertile age, 
and seems an improbable explanation to the presence of anti-HLA class I antibodies with 
high MFI/SFIs in these cases. We selected our cases based on the presence of anti-HLA class 
I antibodies, which are known to occur more frequently with increased parity[74], the high 
frequencies of nulliparous mothers is therefore somewhat unexpected. On the other hand, an 
increased morbidity among neonates of immunized nulliparous mothers is seen in RhD 
immunization[163], indicating that a breach of maternal tolerance may be more severe in the 
first pregnancy. Nulliparity is also a risk factor for preeclampsia[164, 165], and associated 
with increased neonatal mortality and SGA neonates[166]. The passage of fetal cells into 
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maternal circulation may enhance tolerance in subsequent pregnancies[36], and lack of such 
an effect might be one possible explanation for the high frequency of nulliparous mothers in 
our materials, and could also be in line with the high antibody reactivity. 
 
4.3.3 Higher Levels Rather Than Unique Specificities Compared to Controls 
Another important finding in these studies is that both case groups had antibody specificities 
that were also present in the control groups, implying that the antibody levels, reflected by the 
high SFI/MFI values, and not certain specificities, could be associated with a worse outcome 
among the cases. This is in line with a retrospective study of FNAIT cases from 2016[155], 
where the group with ICH had higher levels of both anti-HPA-1a and neonatal antigen-
specific anti-HLA class I antibodies compared to the anti-HPA-1a immunized group without 
ICH (although the anti-HLA class I antibody comparison was not statistically significant). In 
paper I, the antibody levels were quantified as a median value of all reactive beads with 
SFI>999. In paper II, we could further distinguish beads with paternal-specific epitopes, and 
compare the MFI values on beads coated with such epitopes versus those without; we found 
that beads without mismatched epitopes had lower MFIs (Fig. 4), higher paternal-specific 
MFI levels in multiparous mothers (Fig. 5b), and a tendency towards a increased paternal-
specific MFI associated with lower platelet counts in the neonate (Fig. 5a). These findings 
strengthened the relevance of the higher MFI values in cases compared to controls.  
 
4.3.4 Correlation to Clinical Data 
In paper I, both cases with and without signs of bleeding had severe thrombocytopenia, and 
there was no correlation between platelet count and SFI values. Though not significant, there 
was a tendency towards lower SFI values in the cases with bleedings excluded, but this 
analysis was hampered by the fact that 9/23 cases had missing or inadequate data available on 
bleeding outcomes (Table 2). SFI levels correlated with increased maternal age, but there was 
no statistical significant difference in levels comparing nulliparous and multiparous mothers. 
In paper II, such a difference could be demonstrated, as multipara had higher fetal/paternal-
specific MFI values. There was also a tendency towards higher specific MFI values in cases 
with ICH, but again, missing data made the comparison flawed, since the diagnosis could not 
be ruled out in 13/50 cases, and only 2 of the ICH cases had genotyping data available (Fig. 
5). One interesting observation was the decreased platelet counts in cases with mismatched 
HLA B-27, and the high frequency of the HLA-B27 antigen among the case mothers; HLA-
B27 is associated with several autoimmune diseases[167], and this finding should also be 
tested in larger materials.  
 
4.3.5 Translating High Reactivity in Luminex to Biological Relevance 
An important question is how these increased antibody levels as measured using Luminex 
can be translated into effects in vivo. One major limitation of the Luminex assay is that the 
antigens expressed on the beads may have undergone conformational changes, and antibody 
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binding in vitro may be affected by both loss of epitopes and unnatural expression of cryptic 
epitopes; there is therefore a chance that antibody binding in the Luminex will not reflect the 
true binding of these antibodies in vivo[168]. This is also suggested to be one explanation to 
the poor correlation between IgG MFI levels and complement binding measured in 
Luminex[169, 170], an assay that can be used in transplantation settings. To confirm the 
biological relevance of the reactions in Luminex, one could also add other, cell-based, 
methods of measuring anti-HLA class I antibody binding, such as the complement-dependent 
cytotoxicity assay (CDC)[171], and flow cytometry cross-matching (FCM)[172]. However, 
in CDC only complement-activating antibodies are detected, and FCM may have “false” 
positive results of no relation to outcome (as investigated in a transplantation setting)[173].  
Aside from different ways of measuring the presence of antibodies, another approach to 
confirm the relevance of such findings is to predict the binding affinity of the fetal-paternal 
HLA class I peptides to maternal HLA class II molecules. This is attempted by the “predicted 
indirectly recognizable HLA epitopes presented by HLA class II” (PIRCHE-II) algorithm, 
but is only available for the HLA-DRB1 alleles. Increasing PIRCHE-II numbers were 
associated with an increased percentage of mismatched HLA class I antigens that had elicited 
antibody production, but highly immunogenic HLA molecules had similar PIRCHE-II 
numbers as less immunogenic molecules[174]. 
Another possibility is to investigate other effector functions of HLA class I antibodies, in 
addition to complement binding. In anti-HPA-1a alloimmunization, decreased fucosylation 
has been shown to be associated with enhanced phagocytosis of platelets[105], and while this 
was not shown for anti-HLA class I antibodies formed after pregnancy, it has to date not been 
investigated in other cohorts. Along that line, it could be interesting if certain anti-HLA class 
I antibody specificities could also bind endothelial cells, and if this could mediate a higher 
risk of ICH, similar as with anti-αvβ3 antibodies. There were several neonates with ICH 
among our cases: 2/23 neonates in paper I, and 5/50 in paper II. Although these cases were 
also severely thrombocytopenic, it is known from the transplantation setting that anti-HLA 
class I alloantibodies may induce vascular damage[175], and it would be interesting if also 
maternal anti-HLA class I alloantibodies could have similar effects in some cases.  
A central question that arises from studies on anti-HLA class I antibodies and FNAIT is why 
only platelets are affected by the presence of these antibodies. In contrast to HPA antigens, 
HLA class I is expressed on near all nucleated cells. If present in the fetal circulation, anti-
HLA class I antibodies should therefore be able to bind fetal cells and tissues 
indiscriminately. There is considerable intra- and interindividual variation in the platelet HLA 
class I antigen expression [176-180], but due to the relative abundance of platelets compared 
to other cells in the circulation, it is estimated that two thirds of the HLA class I antigen in 
blood is carried by platelets[75], and one possible explanation is that they may function as a 
“buffer” for the circulating anti-HLA class I antibodies.  
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4.3.6 Limitations  
The major limitation to both papers is the relevance of the controls groups. Neither of the 
control groups was matched with regards to age or parity. In paper II, we only had access to 
genotyping data for 5 controls, which hindered an adequate comparison of antibody binding 
to beads expressing fetal/paternal specific epitopes. Furthermore, the study would have 
benefitted from genotyping data on the fathers, as unresolved cases could have been due to 
antibodies directed against paternal antigens that the fetus did not inherit. There is probably 
also an effect of selection bias in both studies, and different sampling times between cases 
and controls could possibly have affected the comparisons, and also hinders any causal 
inference (as discussed in the chapter on methodology). Another limitation is that the 
Luminex assay is only a semi-quantitative method, although it is often interpreted in a 
quantitative manner.  
 
4.4 IMPLICATIONS 
These two studies demonstrate that although rare, suspected FNAIT associated with anti-
HLA class I antibodies are cases with severe clinical outcomes. However, both studies suffer 
from significant limitations, and to be able to answer the underlying research question of 
causality, prospective studies are needed. Genotyping data and the epitope mapping approach 
used in study II proved essential to evaluate the antibody reactions, and would be useful to 
implement in any prospective studies, as it ensures that the antibodies evaluated are in fact 
specific against paternally inherited antigens. We could demonstrate such paternal specificity 
for our cases in study II, and this supports the hypothesis that FNAIT could be caused by 
anti-HLA class I antibodies. However, it is important to keep in mind both the high frequency 
of these antibodies in healthy pregnancies, and that our cases also had other factors that could 
mediate thrombocytopenia.  
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5 RESULTS AND DISCUSSION STUDY III 
To investigate a possible role of reduced platelet function in FNAIT, this project consisted of 
two main parts - to compare neonatal platelet function to adult, and to investigate the 
potential effects of maternal anti-HPA-1a antibodies on fetal platelets. The comparisons of 
neonatal and adult platelet function confirm and expand upon notions from previous studies, 
and is an important backdrop to the potential effects of anti-HPA-1a antibody on platelets in 
FNAIT. The antibody effects were tested using different approaches, and when utilizing a 
monoclonal anti-HPA-1a antibody, we could demonstrate a decreased fibrinogen binding, 
which could affect the neonatal hemostatic balance.  
 
5.1 SUMMARY OF MAIN FINDINGS 
Functional assays on platelet function in adult and cord blood revealed differences in 
aggregation, as measured in Multiplate, a reduced change in expression of glycoproteins with 
activation, as measured in flow cytometry, and discrete differences in hemostatic functions, 
as mesured in Rotem. We also evaluated the HPA-1a epitiope expression, by comparing 
MFIs from an anti-CD61 antibody specific for the HPA-1a allele; we found that there was a 
tendency towards increased expression in neonates as compared to adults, and that the 
expression increased with activation of the platelets. Together, these data point towards a 
decreased in vitro platelet reactivity of neonatal platelets, while the limited differences in 
Rotem, which evaluates the hemostatic function more as a whole since it depends on both the 
platelets and coagulation factors, hint towards compensatory mechanisms and enhanced 
neonatal hemostasis. In the presence of a monoclonal anti-HPA-1a antibody, fibrinogen 
binding was reduced, and the effect corresponded to the HPA-1a antigen expression as 
expected. However, this reduction in fibrinogen binding seemed to have limited functional 
consequences, as measured by CD62-P up-regulation.   
 
5.2 DISCUSSION 
5.2.1 Hypo-Responsive Platelets and Enhanced Primary Hemostasis in Neonatal 
Blood 
The decrease in platelet reactivity observed here and in other studies[181] could be due to 
multiple mechanisms. Neonatal platelets have recently been shown to have a decreased 
number of dense granules[182], with a lower concentration of ADP and serotonin[183]. The 
release of these dense granules upon stimulation with thrombin has also been shown to be 
lower in neonates compared to adults[184]. Reports have also shown impaired signal 
transduction pathways in neonatal platelets, affecting the ability to mobilize intracellular 
calcium, G-protein mediated responses, and the pathways that involve thromboxane A2 
(TXA2) synthesis[185]. The impairment of these signaling pathways can result in a reduced 
up-regulation of adhesion receptors (such as p-selectin), and a lower production of TXA2 
with activation, which again can contribute to the hypofunctionality[186].  
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Despite these differences in in vitro platelet reactivity, neonates normally have no increased 
bleeding tendency, and actually have an enhanced primary hemostasis, as measured in PFA-
100[187] and Rotem[148]. The enhanced primary hemostasis has been attributed to higher 
levels of vWF, presence of high-molecular weight vWF multimers, higher hematocrit 
levels[143], and higher mean corpuscular volume (MCV)[186, 188]; most other hemostatic 
factors are decreased in neonates compared to adults, except for increased levels of FVIII 
immediately after birth, and unchanged levels of FXIII[189]. The high vWF levels may 
enhance adhesion capacity, and an all together more efficient primary hemostasis may 
compensate for decreased platelet reactivity[186].  
Our samples of adult and neonates also reflect these previous findings: Though with 
decreased platelet reactivity and aggregation (Fig. 1, Fig. 2, Table 1), we found enhanced 
primary hemostasis reflected by shorter clotting times in Rotem (Supp. Fig. 1). We did not 
evaluate the concentrations of coagulation factors, but the neonates had statistically 
significant higher MCV and hematocrit levels (Supp. Table 1). The neonates also had higher 
platelet counts (not statistically significant), and higher lymphocyte counts, which may 
enhance aggregation[190]; this might have helped balanced out differences in platelet 
reactivity. Conversely, red blood cell counts and mean platelet volumes (MPV) were reduced 
in the cord blood. In our data, there was no correlation with MPV and aggregation (Suppl. 
Fig. 2), although such correlations have been suggested in older studies[191, 192].  
 
5.2.2 Results From Experiments with Maternal Plasmas 
To investigate whether anti-HPA-1a antibodies could affect platelet function, we tried several 
approaches. For set-up experiments, we first tested the standardized, pooled anti-HPA-1a 
plasma (NIBSC) using Multiplate on healthy adult donors and cord blood, with ADP and 
TRAP as stimuli: This gave variable results, with even increased aggregation in some 
samples. AB serum induced variability in aggregation with a different kinetic in the 
aggregation curves (Figure 10), and proved inappropriate as a control (CV% 1-21% vs. 3-6% 
without AB serum). Overall the trend was a decreased aggregation with NIBSC compared to 
normal tests (no serum, PBS), but with less effect than AB serum (Figure 11). Rotem analysis 
showed a shortening of clotting time with NIBSC, for both adult and cord blood (data not 
shown). 
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Due to the inappropriate controls and variable effects, we next tried maternal plasmas 
containing anti-HPA-1a antibodies at different concentrations (sample B1, 43 IU/mL; sample 
B2, 130 IU/mL; sample B3, 258 IU/mL), with AB plasma from a single donor as control. 
Readouts were aggregation in Multiplate, Rotem parameters (CFT, CT, MCF), and CD62-P 
up-regulation in flow cytometry. Three adult donors of each HPA-1a genotype were tested 
(Figure 12). Compared to the controls (AB plasma and PBS), there was a decrease in 
aggregation, but the effect was unspecific with regards to HPA-1a type, as both HPA-1a 
positive and negative platelets were affected. For two donors we also added the donor’s own 
EDTA plasma as an extra control, which did not affect aggregation (data not shown). The 
decrease in aggregation with maternal plasmas did not correlate with binding of the 
antibodies, as HPA-1a positive platelets had a tendency towards higher anti-IgG stainings 
than HPA-1bb platelets, and one plasma with low anti-IgG staining (B1) also severely 
affected aggregation. In anti-CD62-P stainings, we found increased expression of CD62-P on 
unstimulated platelets, but a lower CD62-P increase with TRAP stimulation, on both HPA-1a 
positive and negative platelets.  
Unpurified plasma may contain IgM, anti-HLA class I antibodies, different levels of platelet 
activators such as ADP and fibrinogen, and other factors that could have affected these 
results. We therefore also tested purified IgG from maternal plasmas, that were screened 
negative for anti-HLA class I antibodies, with the elution buffer as control. In these 
experiments the anti-IgG staining was also unspecific; the purified IgG bound to both HPA-
1aa and HPA-1bb platelets, and there was a reduced CD62-P up-regulation with TRAP 
stimulation on both platelet types (data not shown). For these experiments, the total IgG 
concentration was ca. 120 μg/mL (measured by spectrophotometry[193]), but the final anti-
HPA-1a IgG concentration was unknown.  
 
Figure 10: Aggregation curve with TRAP as 
stimuli after incubation with AB plasma. The two 
curves should run in parallel and increase, and not 
diverge or decrease. 
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Figure 11: Aggregation in Multiplate, relative to PBS 
for adult and cord blood samples (both n=12). Both 
NIBSC and AB serum decreased the aggregation.  
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To summarize, results from these experiments indicated that while there was some inhibitory 
effect on the platelets with anti-HPA-1a antibodies, the selected controls were not 
appropriate, and the different plasmas containing anti-HPA-1a antibodies gave unspecific 
effects with regards to HPA-1a type. This is in line with previous studies on platelet function 
performed with plasmas[138]. The unspecific effects may possibly be explained by anti-
HPA-1a antibodies with lower affinity; in addition to the presence of IgG with other 
specificities, this might be enough to block high affinity antibodies from binding to HPA-1a, 
while simultaneously the binding may be too weak or unspecific to elicit a substantial 
blocking effect restricted to HPA-1a positive platelets. Furthermore, undisclosed factors 
present in plasma may have affected the results. Although not reflecting the (patho-) 
physiological presence of anti-HPA-1a antibodies in vivo, it was apparent that a monoclonal 
anti-HPA-1a antibody would be the best approach to investigate the potential effects of anti-
HPA-1a antibodies on platelet function. 
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Figure 12: Results from experiments with adult donors, n=3 for each HPA-1a type. Left upper panel: 
Multiplate aggregation after ADP stimulation with maternal plasmas of different anti-HPA-1a titers (B1-
B3), AB plasma from a single, random donor, and PBS. Right upper panel: Anti-IgG MFIs using the same 
samples showed a inconsistent tendency towards HPA-1a specific binding of the IgG present in the 
maternal plasmas. Left lower panel: CD62-P MFIs from samples without stimulation, relative to AB 
plasma, indicating an up-regulation of CD62-P on unstimulated platelets. Right lower panel: CD62-P MFIs 
from TRAP stimulated samples relative to AB plasma, indicating a lower up-regulation of CD62-P in the 
presence of anti-HPA-1a antibodies. For all figures: Full circle=HPA-1aa, half circle=HPA-1ab, empty 
circle=HPA-1bb. 
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5.2.3 Effects Mediated by a Monoclonal Anti-HPA-1a Antibody 
When incubating with the monoclonal anti-HPA-1a antibody (26-4), we found decreased 
fibrinogen binding to washed platelets (Fig. 3A,B), and a reduced anti-PAC-1 binding in 
whole blood, indicating a blocking of the active confirmation of the fibrinogen receptor 
GPIIb/IIIa by 26-4 (Suppl. Fig. 5). These effects were consistent with regards to HPA-1a 
type, with increased inhibition for HPA-1aa platelets compared to HPA-1ab platelets, and 
with little effect on HPA-1bb platelets, which also fit with the HPA-1a specific binding of 26-
4 to platelets (Suppl. Fig. 4). 
Considering the earlier published data on the 26-4 antibody and reduced aggregation[56], 
these findings are not unexpected, but this is still the first study to use a monoclonal anti-
HPA-1a antibody derived from an immunized mother to demonstrate decreased fibrinogen 
binding as a potential aspect of FNAIT. However, in a study from 1984[137], similar results 
were actually demonstrated using polyclonal IgG and Fab fragments isolated from two 
immunized mothers. The fibrinogen binding was quantified as association of radiolabeled 
fibrinogen to a platelet pellet, and similar results were observed for HPA-1a homozygous and 
heterozygous platelets, indicating a less sensitive assay compared to flow cytometry, where 
the fluorochrome-conjugated fibrinogen is measured on a single cell-level. Given the possible 
implications of these findings, and the potential to further decipher underlying mechanisms 
using a monoclonal antibody, it may be worth repeating and expanding these experiments 
from the 1980s.  
 
5.2.4 Does Anti-HPA-1a Antibody Mediate Signaling or Blocking Effects? 
After incubation in whole blood, we found a marginal effect on CD62-P up-regulation with 
the 26-4, and the effect was most pronounced on platelets with a low stimulation (TRAP 10 
μM) (Fig. 3C). This could indicate that the blocking effect of 26-4 may be overriden by a 
strong stimulus, which could fit with a form of allosteric hindrance. This is in line with a 
study from 2009, investigating the effect of anti-HPA-1a on endothelial cell spreading[51]: 
purified anti-HPA-1a IgG fractions affected cell spreading, but as opposed to anti-CD61 
antibodies, the anti-HPA-1a antibodies had no effect on cell adhesion; the authors suggest 
that this could be due to a signaling, rather than blocking effect of the human anti-HPA-1a 
antibodies. It would be useful to include an anti-β3 antibody (such as anti-CD61) as 
comparison to the 26-4 antibody in future analyses; this could help discriminate effects of 
different levels of blocking of the β3-integrin.  
Another hint towards signaling effects mediated by anti-HPA-1a antibodies is results from 
GPIIb/IIIa inhibitors such as Abciximab (chimeric mouse-human anti-β3 Fab-fragments), 
which has been shown to decrease fibrinogen binding while simultaneously lead to a transient 
increase in agonist-induced CD62-P expression, without effect on resting platelets[194]. The 
authors postulated an effect of increased mass of protein in α-granules with uptake of 
Abciximab leading to increased release of granules, while others have also suggested an 
activation of GPIIb/IIIa by Abciximab, with subsequent increased fibrinogen binding and 
aggregation[195]. GPIIb/IIIa inhibitors may exert their effects depending on half-life and 
affinity to their epitope on the GPIIb/IIIa receptor[196], extrapolating results from such 
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studies to effects of anti-HPA-1a antibodies in FNAIT is therefore not ideal as both half-life, 
epitope, and binding affinity differ. However, some anti-HPA-1a antibodies have been shown 
to have activating effects[142], and possibly there can be a combination of β3-blocking and 
signaling effects, depending on the affinity of the anti-HPA-1a antibodies, and activation 
status of the platelet. 
 
5.2.5 Limitations 
If anti-HPA-1a antibodies can increase CD62-P expression, this marker may not be suitable 
as the only read-out when investigating the effects of these antibodies on platelet function. 
One could consider other flow cytometry platelet activation markers, such as CD63, which is 
expressed upon lysosome release[197], monocyte-platelet aggregates, which forms after 
degranulation of platelets[198], and other functional assays, such as Rotem. Although 
neonatal peripheral blood and umbilical cord blood have been shown to be comparable with 
regards to activation[145], another limitation of the study is the different sampling techniques 
for neonatal and adult blood. There will be different flow conditions when sampling from the 
cubital vein and from the placenta, and this may affect platelet activation. For the last sets of 
experiments (Fig. 3), we also used citrate tubes for adults, and bags containing citrate buffer 
for the cord blood, which potentially also could affect activation. 
 
5.3 IMPLICATIONS 
The limited and variable effects of plasma containing anti-HPA-1a antibodies, both in our 
hands and in previous studies[138], indicate that the in vivo effects of polyclonal anti-HPA-1a 
antibodies are variable, and may depend on binding affinity to the HPA-1a antigen. The 
monoclonal 26-4 used in our study is selected by its high affinity to the HPA-1a antigen, 
while in vivo, several antibody clones, also with reduced binding affinity, will be present, 
possibly reducing any effect by competitively blocking the binding of high-affinity anti-
HPA-1a antibodies to the HPA-1a antigen. Monoclonal antibodies are probably best for 
deciphering effects on platelet function in relation to FNAIT, but the effects of other human 
monoclonal antibodies should also be tested. Furthermore, it is important to use umbilical 
cord blood or neonatal platelets for such studies, since the GPIIb/IIIa expression is 
lower[145], and the neonatal hemostatic balance differs from that in adults.  
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6 RESULTS AND DISCUSSION STUDY IV 
In this study we focused on the most feared complication of FNAIT, an intracranial 
hemorrhage. There is a continuous debate on whether screening for FNAIT to prevent ICH 
should be implemented, and one of the arguments against screening is that the true risk of 
ICH in index cases of FNAIT is unknown. To get an indication of how often an ICH is 
associated with FNAIT,  we used the Swedish Neonatal Quality register (SNQ) to assess the 
frequency of maternal platelet alloimmunization in a population of neonates with intracranial 
hemorrhage.  
 
6.1 SUMMARY OF MAIN FINDINGS 
Between 2003 and 2012, 286 neonates with an ICH born at or after 32 weeks of gestation 
were registered in the SNQ. Of the mothers, 278 could be contacted, and we received samples 
from 120 mothers. We excluded cases where the ICH had occurred after the neonatal period 
(n=2), and cases where the neonatal ICH diagnosis was uncertain when reviewing hospital 
records (n=15) (Fig.1). When comparing hospital records to data in the SNQ (n=93), we 
found that the diagnosis of ICH could be verified in 84% of reviewed cases. Of the 105 
relevant samples, we found two HPA-1a antigen negative (HPA-1bb) mothers, of which one 
had detectable anti-HPA-1a antibodies and a severely thrombocytopenic neonate. The other 
HPA-1bb mother had delivered a boy with a large infarction and secondary bleedings in the 
CNS, and he was not thrombocytopenic. Two other mothers had detectable antibodies, anti-
HPA-5b antibodies, and anti-HPA-5b antibodies together with anti-HPA-15a antibodies; both 
of these two neonates had moderate thrombocytopenia (Table 3). When reviewing the clinical 
data from the SNQ register and hospital records, we found that thrombocytopenia in general 
was rare; 5.3% (n=14/262) were diagnosed as thrombocytopenic, and 8.5% had platelet 
counts <50x109/L (n=5/59) noted in hospital records. Furthermore, we found a rather 
heterogonous case population with regards to other clinical data, and a high frequency of 
factors with a known association with ICH, such as asphyxia, trauma, and infections.  
 
6.2 DISCUSSION 
6.2.1 Possible Limitations that Could Explain the Low Frequency of Platelet 
Alloimmunization 
This study is the first of its kind, and we did therefore not have any strong preconceptions on 
the frequency of anti-HPA immunized mothers among the selected cases of neonates with 
ICH. Still, compared to prospective studies on FNAIT[104], the frequency is lower than 
expected, and several limitations could explain this finding: 
 
6.2.1.1 The SNQ Register 
The basis of the study was the SNQ register, and one apparent possibility is that not all 
relevant cases were registered. The registry was implemented gradually, and we estimate that 
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about 75% of all births should be covered in the study period. Although there is a possibility 
that some cases were not included due to low coverage of the registry, there is no reason to 
suspect that cases with platelet alloimmunization should be less likely to be registered. The 
registry covers neonates admitted to a neonatal intensive ward (NICU), and the chances that a 
live neonate should be diagnosed with an ICH without being admitted to NICU, or that a 
neonate with ICH should succumb after birth but before admission to NICU, are small.  
 
6.2.1.2 Intrauterine Fetal Death 
We also reviewed cases of intrauterine fetal death (IUFD) in the Stockholm region in the 
study period, and found a low frequency of signs of ICH among the investigated cases 
(n=9/745), born from 22 weeks of gestation. We expect cases of IUFD in Stockholm to be 
representative of the rest of Sweden. Although the frequency of ICH in cases of IUFD can be 
higher than the frequency of ICH among live born neonates, the frequency of IUFD in itself 
is low in Sweden, and it is not likely that we missed a majority of the FNAIT cases in 
Sweden due to IUFD. However, in future screening studies on FNAIT, cases of IUFD should 
also be included. 
 
6.2.1.3 Higher Frequency of Platelet Alloimmunization in ICH in Very Premature 
Neonates? 
The selection criteria of gestational age of at least 32 weeks at birth could have affected our 
results, as ICH due to FNAIT can develop early in gestation. In a retrospective study of ICH 
and FNAIT, 67% (29/43) were born before week 37, and while only four were born before 
week 28[153], excluding cases with ICH born before week 32 could be a possible 
explanation for the low number of cases associated with FNAIT in our study population. On 
the other hand, a study on frequency of anti-HPA in a cohort of suspected fetal ICH without 
demonstrated thrombocytopenia confirmed FNAIT in 2/33 cases[199]; this low frequency is 
in line with our findings, and indicates that platelet alloimmunization is rare also in premature 
neonates with ICH. 
 
6.2.1.4 Asymptomatic Cases 
The most likely reason for the low frequency of FNAIT in our selected population of 
neonates could be that neonates without symptoms of their ICH would not be included. The 
clinical relevance and impact of such ICHs are not known, and probably very variable. The 
frequency also would depend on detection techniques; an MRI examination can detect signs 
of ICH in up to 26% of presumably healthy term neonates without clinical signs of ICH[154], 
while with less sensitive techniques such as ultrasound, the frequency is much lower[200]. It 
would be important to also include asymptomatic cases of ICH in screening studies on 
FNAIT, to get the full clinical spectrum of this condition. Retrospective investigation of 
clinical data might lead to an underestimation of frequency, with an overrepresentation of the 
most severe cases. 
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6.2.1.5 Sampling Interval and Lack of Cross Matching 
The mothers were sampled during 2015, while the oldest child was born 2003. Since we 
serotyped all mothers for the HPA-1a antigen, it is highly unlikely that we missed cases with 
anti-HPA-1a immunization, but due to the long interval, there is a possibility that we missed 
cases with other anti-HPAs than anti-HPA-1a, as antibodies may disappear over time. 
Furthermore, we only tested for antibodies against HPA-1, HPA-2, HPA-3, and HPA-15 
antigen systems, and antibodies against rare, private HPAs would not be identified without 
cross matching with paternal platelets. Alloantibodies against low frequency human platelet 
antigens is rare, also in cases of suspected FNAIT [201], and is as such not an apparent 
reason for the low frequency of anti-HPA in our study. 
 
6.2.2 High Morbidity in Cases of ICH 
By comparing to the background population, it was evident that our cases of neonates with 
ICH had a high mortality and morbidity, and the register data also revealed a multitude of 
different factors that can be associated with an ICH. The frequency of mothers with an HPA-
1bb genotype at approximately 2% suggests that FNAIT was not overrepresented among 
these neonates with ICH. Although neonatal ICH due to FNAIT has received attention due to 
its potential severity, and might seem easy to prevent, or at least anticipate, investigation of 
and attention to other preventable causes of ICH are also justified.  
 
6.3 IMPLICATIONS 
This study suggests that FNAIT is rare in cases of clinically recognized ICH. However, it also 
demonstrates that cases of neonatal ICH with maternal platelet alloimmunization are difficult 
to identify retrospectively. Well-designed prospective screening studies of sufficient size are 
necessary in order to answer the main underlying research question of the occurrence of ICH 
in FNAIT, and to gain new knowledge on a potentially severe condition. The results from this 
study indicate that such screening studies would require thorough monitoring of fetal and 
neonatal health to get the full clinical picture of FNAIT. 
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7 METHODOLOGICAL APPROACHES AND 
CONSIDERATIONS 
 
7.1 PLATELET ALLOANTIBODY DETECTION USING MAIPA 
Study I, II and IV all depended on precise detection of maternal anti-HPA antibodies.  
The Monoclonal Antibody-specific Immobilization of Platelet Antigens (MAIPA) assay has 
for long been the cornerstone for detection of platelet antibodies, and has since its 
introduction in 1987[202] undergone several modifications to increase sensitivity, and reduce 
variation between laboratories.  
MAIPA is a glycoprotein-specific assay, and its properties are dependent on a reliable panel 
of platelet antigens, some of which are rare in a general population. Another limitation is that 
plasma antibodies and monoclonal antibodies may compete[203]; these limitations may be 
overcome by selecting monoclonal antibodies that target different epitopes, and by 
substituting platelets with target cell lines[204], recombinant proteins[205] or purified platelet 
peptides (as used in SPR to detect low-avidity anti-HPA-1a antibodies [206, 207]) [208].  
Some anti-HPAs are difficult to detect, such as antibodies targeting the HPA-3 and HPA-15 
antigen systems. In the case of anti-HPA-3a, this can be due to unstable epitopes, that require 
an intact three-dimensional structure of the αIIbβ3 integrin, which may be lost after 
solubilizing[209], fixation[210], and storage of platelets[211]. The presence of anti-HLA 
class I antibodies may also interfere with detection[209]. For anti-HPA-15 antibodies, the 
CD109 protein, which carries the epitope, is lowly expressed compared to other HPAs, the 
expression varies among donors[212], and is dependent on proper storage conditions [212].  
EDTA was recently shown to decrease sensitivity of MAIPA[213, 214]. EDTA is a chelating 
agent, and may disrupt the αIIbβ3 integrin as the heterodimer complex is dependent on 
calcium. The effects of EDTA depend on time of exposure and temperature, with little 
dissociation at temperatures below 25°C [215]. Though EDTA was shown to only marginally 
affect the beads-based MAIPA assay used in study IV, where calcium and magnesium is 
added to the assay buffer[216] (Figure 13), this highlights the need to be aware of different 
properties of buffers and reagents used in assays to detect anti-HPA antibodies. 
As part of the routine investigations for FNAIT, samples on both parents are collected, so that 
paternal platelets may be used in the MAIPA. This ensures that antibodies against rare and 
private platelet antigens may be detected. Cross-matching against paternal platelets was 
performed for most cases in study I and II, as the cases were referred due to clinical 
suspicion. In study III, we only collected samples from the mothers; we could exclude 
antibodies against HPA-1a (as all were serotyped for the antigen), which was the alloantibody 
of focus for the study, but antibodies against rare and private epitopes could not be excluded.  
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Though MAIPA is considered the gold standard to detect platelet antibodies, each laboratory 
has its own protocol, and it is constantly renewed to improve sensitivity and specificity. This 
is also reflected by the studies included in this thesis: In study I, a conventional MAIPA was 
used to rule out anti-HPA immunization, and the same laboratory updated to a beads-based 
version in study IV for increased sensitivity to detect anti-HPA antibodies[216]. For study II, 
the analyses were performed in Tromsø, Norway, where the laboratory has other protocols 
for detection and quantification of antibodies[99, 217]. In addition to taking advantage of the 
high affinity between biotin and streptavidin (SA) to capture antigen/antibody complexes 
(Figure 13), and using PE-conjugated anti-human-IgG for detection, the methods also differ 
in the capture antibodies used, and by separate incubation of patient plasma samples and GP-
specific antibodies[216]. Although it can potentially be seen as a drawback that different 
methods were used, it is the result of constant improvement in the laboratories, and the best 
methods available at the time were applied.  
 
7.2 OTHER METHODS FOR ALLOANTIBODY DETECTION 
With MAIPA’s limitations, multiple methods are needed to diagnose the presence of anti-
HPA antibodies in sera with high sensitivity and specificity. Platelet immunofluorescence test 
(PIFT) is another established method to detect anti-platelet antibodies[218]. Here, antigen-
positive platelets are incubated with sera, before anti-IgG antibodies, labeled with fluorescent 
molecules such as PE, are used to detect antibody-antigen complexes (by microscopy or flow 
cytometry). Although fast and easy to perform, as a whole-platelet method it does not allow 
for discrimination between different anti-platelet antibodies (such as anti-HLA and anti-
HPA), and possibly has an insufficient specificity for anti-HPA alloantibodies[208]. It is 
primarily used as a screening test together with MAIPA or other more anti-platelet antibody 
specific methods (as in study I).  
Another assay that can be used for detection of anti-platelet antibodies is enzyme-linked 
immunoassay (ELISA). There are many versions of ELISA, and depending on the capture 
antigens, antibodies of different specificities may be detected. Pak-12 (Immucor GTI 
Diagnostics, Waukesha, WI, USA), for detection of anti-HPA antibodies, and Quikscreen 
(Gen-probe GTI Diagnostics Inc, Norcross, GA, USA)[219] for detection of anti-HLA class I 
antibodies were used in study I to identify mothers with only anti-HLA class I antibodies. 
The basic principle of the assay used in the studies in this thesis is as follows: Patient plasma 
(or serum) is added to a microwell plate, with wells coated with HLA class I (or HPA) 
glycoproteins to which antibodies in the plasma can bind. Anti-IgG conjugated to ALP is 
then added and incubated, before a substrate (PNPP, p-nitrophenyl-phosphate) is added. 
Washing is necessary between each step to remove unbound materials. The use of secondary 
(anti-IgG) antibody amplifies the signal as each primary antibody contains multiple epitopes 
that can be bound by the secondary antibody (known as an indirect ELISA assay). The optical 
density of the developing color is measured in a spectrophotometer. 
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An example of a screening method for detection of anti-HLA class I antibodies, used in study 
II, is FlowPRA (OneLambda, CA, USA). Here, the basic principle is HLA class I antigens 
coated on several beads, covering the most common antigens; antibodies directed against the 
non-polymorphic region of the HLA class I molecule is used to immobilize the antigens, 
leaving the polymorphic domains for antibody binding. Patient serum is then incubated with 
the mix of beads, before anti-IgG, conjugated with fluorescent molecules (FITC), is added. 
Fluorescence is subsequently measured in a flow cytometer, and the assay gives an overall 
MFI. Both FlowPRA and Quikscreen/ELISA are sensitive methods, primarily used to detect 
the absence or presence of HLA class I antibodies.  
 
7.3 DETECTION OF ANTI-HLA CLASS I ANTIBODY SPECIFICITIES  
In study I and II, anti-HLA class I antibody specificities from screened positive mothers were 
investigated in detail. A Luminex microbead assay was applied in both studies (LABScreen 
Single Antigen, One Lambda, CA, USA). Here, different HLA-class I antigens are coated on 
fluorescent beads, to cover the most common antigens in the population (in total 97 antigen 
beads). Fluorescent anti-IgG (PE) is used to detect antibodies, allowing for detection of an 
anti-IgG signal that can be ascribed to a particular bead. Although each bead is coated with a 
specific antigen, epitopes can be shared between antigens, which explain the often seen 
reactivity to multiple beads, even though the tested antibody has arisen from immunization 
against a single antigen. In study II, these patterns were confirmed by dilution experiments, 
where after diluting the samples at 1:10, 1:50, and 1:100, the reactivity remained consistent. 
To compare between different samples over time, Quantiplex beads allows for 
standardization of MFI values (into SFIs). Though not validated as a quantitative assay, 
results are often interpreted in a semi-quantitative manner[220-222]. The binding of antibody 
to their respective epitopes will be reflected by the MFI values, and though different epitopes 
may be expressed at different frequencies, this should not affect the MFI signals as long as 
the binding sites are not completely saturated.  
Cut-off for the Luminex is often set to an SFI/MFI >999. Though somewhat arbitrary, values 
below this threshold are traditionally considered unspecific. In study I, this was the cut-off 
initially used, but a higher cut-off was also applied, to visualize the differences in high levels 
of anti-HLA class antibodies between the groups. In study II, no cut-off was applied. In both 
studies, the statistical analyses provided similar results when comparing antibody levels 
between the groups, independent of the MFI>999 cut-off.  
Median MFI for all beads (with MFI>999) was used as a measure of HLA class I antibody 
level in study I. Without genotyping data, we considered this measure as the best indicator of 
reactivity against immunizing HLA class I antigens, as most reactivity was thought to be 
directed against foreign/paternal HLA class I antigens. This overall median MFI was also 
used to compare antibody levels between cases and controls in study II. Here, additional 
genotyping data and epitope mapping (described below) also allowed for comparison of 
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MFIs for beads with paternal/immunizing epitopes versus beads without, and correlation of 
paternal-specific alloantibody levels to clinical data within the case group.  
 
7.4 HPA GENOTYPING  
To support alloantibody findings, and to confirm serotyping of HPA antigens, genotyping of 
relevant HPAs is performed as part of the diagnosis of FNAIT. Genotyping of HPA is 
generally considered reliable and precise with different PCR-based techniques, where the 
particular DNA of interest is amplified and can then be measured. Both in-house and 
commercially available methods are constantly developed to allow for genotyping of new 
antigens and high-throughput testing[223]. For study I: IDHPA (Progenika, Biscay, Spain), a 
multiplex genotyping platform based on Luminex technology was used; for study II the 
technique is described in the following references: cases referred until year 2000[224], cases 
referred later[225]; and for study III and IV: In-house Taqman SNP Genotyping assay 
(Applied Biosystems, MA, USA)[226].  
 
7.5 HLA CLASS I GENOTYPING AND EPITOPE MAPPING 
In study II, maternal and neonatal HLA class I genotyping was performed. The analyses were 
done by an in-house sequence-based typing, and analyzed using the Assign Software 
(Conexio Genomics, Fremantle, Australia)[227]. If genotyping indicated two or more likely 
alleles, the most frequent allele according to data from the Norwegian Bone Marrow Donor 
Registry[228] was chosen for the subsequent analyses. 
Genotyping of HLA class I alleles in study II allowed for assignment of apparently broad and 
unspecific antibody patterns to particular immunizing epitopes, expressed on multiple beads. 
This was made possible by combining the genotyping data with data on HLA class I epitope 
expression. Epitopes not expressed by maternal antigens, and labeled as “antibody reactive” 
in the epitope registry, were assigned as immunizing. The MFI values from the antibody 
assay could then be interpreted as representing reactivity against paternal/immunizing 
antigens, third-party (for instance previous pregnancies), or self-antigens. Epitope data was 
retrieved from HLAMatchmaker (http://www.epitopes.net) and the HLA Epitope Registry 
(http://www.epregistry.com.br/index/databases/database/ABC/) in February 2016 [229].  
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Figure 13: The beads-based MAIPA used in study IV. A) Overview of the beads-MAIPA method. 1) 
Platelets are incubated with plasma containing anti-HPA antibodies. 2) Incubation with biotinylated 
glycoprotein-specific antibody. 3) Platelets are lysed. 4) Incubation with streptavidin-coated beads. 5) 
Incubation with anti-human IgG-PE. B) Example raw data from flow cytometry analysis. Median 
fluorescence intensity on 1000 beads gated in FSC and SSC plot is used as read-out. Representative 
histograms for negative (filled) and positive (unfilled) control samples for anti-HPA-1a, anti-HPA-3a, anti-
HPA-5b and anti-HPA-15b are shown. C) Sensitivity and reproducibility of beads-MAIPA. The same 
negative and positive samples were analyzed at different occasions with test platelets from different blood 
donors. Median fluorescence intensity for negative (unfilled) and positive (filled) control samples for anti-
HPA-1a (HPA-1aa platelets), anti-HPA-3a (HPA-3ab or -3aa platelets), anti-HPA-5b (HPA-5ab platelets) and 
anti-HPA-15b (HPA-15ab and HPA-15bb platelets). D) Comparison of signal-to-noise (positive control 
divided with negative control) for beads-MAIPA and MAIPA. For beads-MAIPA the median fluorescence 
intensity is used as read-out and for MAIPA the optical density at 450 nm is used. Heavily adapted from[216]. 
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7.6 ASSAYS FOR EVALUATING PLATELET FUNCTION 
7.6.1 Multiplate 
We used Multiplate (Roche Diagnostics, IN, USA) as one measure of platelet function. 
Multiplate measures change in electrical resistance as the platelets aggregate, known as 
impedance aggregometry. Whole blood (anticoagulated with citrate or hirudin) is added to a 
cuvette containing electrodes, and incubated with a calcium-containing solution, before 
different stimuli are added (such as ristocetin, TRAP, ADP, collagen). Change in impedance 
is measured in arbitrary units over time, in total eight minutes (Figure 14). The assay reflects 
interactions between platelets, red cells, and leukocytes, and has been shown to be sensitive 
for platelet count levels, but not age, gender, ABO blood group, smoking, or use of oral 
contraceptives[190]. For study III, we chose to use ADP and TRAP as stimuli, to investigate 
effects of a weak and more potent stimulus, respectively[230].  
 
 
Figure 14: Exemplary Multiplate output. Change in impedance is measured in two electrodes simultaneously, 
represented by the red and blue curves, and combined into one average measure as area under the curve. 
AU=arbitrary units. The curves show ADP-stimulated adult platelets. 
 
7.6.2 Rotem 
As the blood clot forms during coagulation, fibrin networks increase the viscosity of the 
blood. Viscoelastic methods evaluate this process, by measuring the initiation of the clot 
formation, its elasticity development, and finally the fibrinolysis in real time. The elasticity 
depends on the platelets’ contractile force, hematocrit levels, fibrinogen concentration, FXIII 
(which crosslinks fibrin), and the thrombin generation[230]. For rotational 
thromboelastometry (ROTEM, Tem International GmbH, Munich, Germany) used in study 
III, citrated whole blood is placed in a cup with a rotating pin. Once the blood starts to clot 
and fibrin strands are formed, the rotational force (torque) between the pin and the cup 
increases. Dissociation of the clot decreases the torque. In Rotem, the changes in torque are 
measured optically, and presented as a tracing of the clot formation[231] (Figure 15). A 
variety of inhibitors and activators can be used in Rotem to estimate different parts of the 
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coagulation process. We used EXTEM, which uses tissue factor as an activator of the 
extrinsic pathway, and reflects the clot strength dependent on platelet and fibrin 
interactions[232]. In this way Rotem complements Multiplate, as it is more dependent on 
coagulation factors (in particular fibrinogen), compared to Multiplate.  
 
 
Figure 15: Exemplary Rotem graph, adapted from[233]. CT=Clotting time, representing the latency time 
from adding the start reagent to when the clot starts to form.  CFT=Clot formation time, the time from CT 
until a clot firmness of 20 mm is formed. Alpha-angle=Angle of the tangent between 0 mm and the curve 
when the clot firmness is 20 mm. A10=Amplitude, representing clot firmness, at 10 mins (starting from CFT). 
MCF=Maximum clot firmness, the greatest vertical amplitude, reflecting the maximum strength of the clot. 
LI30=Lysis index at 30 min, the percentage of remaining clot stability in relation to MCF. ML=Maximum 
lysis, the percentage of lost clot stability at any time point or at the end of the assay.  
 
7.6.3 Flow Cytometry 
We used flow cytometry to study the expression of platelet surface receptors in a quantitative 
manner, as the expression of certain surface markers can correlate with platelet function[234]: 
CD41 represents the αIIb part of the GPIIb/IIIa receptor dimer, which functions as the 
receptor for fibrinogen, von Willebrand factor, fibronectin, and vitronectin, when activated. 
PAC-1 recognizes the active conformation of GPIIb/IIIa. CD42a, which represents 
glycoprotein IX (part of the GPIb-IX-V von Willebrand receptor complex), was used as a 
platelet marker in most experiments, and can also be affected by activation status of the 
platelets[235]. However, CD62-P is the most sensitive marker for platelet activation, as it is 
expressed on α-granules, which are released upon activation and degranulation of platelets; 
the CD62-P expression is therefore very low on unstimulated platelets. We also quantified 
CD61/GPIIIa, using an antibody clone that recognizes GPIIIa derived from the HPA-1a 
allele, as an indirect way of quantifying the HPA-1a epitope expression.  
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We used whole blood to compare platelet function in cord blood and adult blood to avoid 
unnecessary manipulation of the platelets, and to analyze the platelets in a more physiological 
milieu (as compared to washed platelets). For study III, citrated whole blood was diluted with 
modified HEPES/Tyrode’s buffer (HEPES 10 mM, NaCl 137 mM, KCl 2.8 mM, MgCl2 1 
mM, NaHCO3 12 mM, Na2HPO4 0.4 mM, BSA 0.35 w/v, glucose 5 mM) 1:50, and stained 
with the following antibodies: Anti-CD42a (eFluor 450, GR-P clone, 
eBioscience/Affymetrix), anti-CD62P (APC, AK4 clone, BD Pharmingen), anti-CD41 (PC7, 
P2 clone, Beckman Coulter), and anti-CD61 (FITC, SZ21 clone, Beckman Coulter). All 
antibodies were titrated to be well saturated, to ensure that variation in MFIs reflected 
changes in antigen expression. To evaluate changes associated with platelet activation, 
samples were incubated with either thrombin receptor activating peptide 6 (TRAP) or PBS, 
together with the antibody mix. After incubation, samples were fixed (1% paraformaldehyde, 
BD Cytofix) to prevent further activation, before dilution with PBS. Samples were kept at 
4°C in the dark and analyzed on BD LSR Fortessa within 48 hours. Ideally all samples should 
be analyzed without delay, but this was not possible logistically. Initial set-up experiments 
demonstrated that the MFIs values remained relatively stable for 48 hours (data not shown).   
To reduce intra-assay variability, samples were run on a low speed, to ensure a flow of single 
cells. For CD61 MFIs, expression was standardized by using Quantum beads (Bangs 
Laboratories, Inc., IN, USA). For other fluorochromes, compensation beads (OneComp 
beads, eBioscience/Affymetrix, CA, USA) were used for monitoring of fluorescence over 
time. For all acquisitions, the same gains/voltages and gating strategies were applied. At least 
10,000 events were recorded to ensure a reliable measure of median MFI values. 
Isotype controls for the antibodies were not used, as only platelets should express the relevant 
epitopes, and larger cells are excluded based on FSC/SSC properties, although unspecific Fc-
binding on platelets cannot be ruled out. We did not include any live/dead staining, as 
previous experiments performed in the group showed up to 95% viability 24 hours after 
sampling, and all samples were stained within 4-6 hours.  
 
Figure 16: Flow cytometry gating strategy. Platelets were selected based on FSC/SSC properties (SSC-A/FSC-A), 
positive anti-CD42a staining (V450-A/SSC-A), and single cell discrimination (FSC-A/FSC-H). MFIs were 
calculated from single cells. 
 50 
7.7 BLOOD SAMPLING 
Platelets are sensitive for sampling methods, mechanical stress, and manipulation. To avoid 
artifactual in vitro activation and reduce variability between donors, we had a consistent 
protocol for sampling of donors, where the first 2 mL was discarded before collecting whole 
blood into citrate tubes. All adult donors were healthy subjects, not smoking or using 
anticoagulants within the last 24 hrs. For neonatal blood we used umbilical cord blood. 
Comparing to peripheral blood, this is of no consequence to the child, and larger amounts can 
be acquired. Neonatal umbilical cord blood and peripheral blood has been shown to be 
comparable with regards to glycoprotein expression[145], although we cannot completely 
exclude that different sampling of adults and neonates could have affected our comparisons.  
 
7.8 FIBRINOGEN BINDING EXPERIMENTS 
To investigate the binding of fibrinogen to platelets, we used washed platelets to minimize 
competition of Alexa-488-conjugated and endogenous fibrinogen. Washing of platelets may 
lead to aggregation, which can alter the expression of relevant antigens, and also needs to be 
avoided to ensure that single platelets are investigated in the flow cytometer. Centrifugation 
on low speeds and the right type of tube (for instance polypropylene) is necessary to 
minimize the risk of aggregation. Although increased levels of platelet activation after 
centrifugations cannot be ruled out, we used a “gentle” protocol for isolating platelets, 
without using platelet inhibitors: Platelet rich plasma was first separated from whole blood 
(200 g, 15 min), and platelets separated from platelet poor plasma by a second centrifugation 
step (400 g, 15 min). 
We evaluated the binding of fibrinogen to platelets by using fibrinogen conjugated with 
fluorescent dye molecules [236, 237]. Washed platelets were simultaneously incubated 1:1 
with anti-HPA-1a/26-4 and Alexa-488 conjugated fibrinogen (ref. no. F13191, Thermo 
Fischer Scientific, MA, USA) for 30 min in the dark at 37°C. Tyrode’s buffer was used as 
control for 26-4. The platelets were then stained and activated before analysis.  
 
7.9 DIFFERENT APPROACHES TO MEASURE ALLOANTIBODY EFFECTS ON 
PLATELET FUNCTION 
To investigate potential effects of anti-HPA-1 antibodies on platelet function, we initially 
tested NIBSC, an international anti-HPA-1a antibody standard, containing pooled, purified 
plasma with anti-HPA-1a IgG from alloimmunized donors (National Institute for Biological 
Standards and Control, product code 03/152, Hertfordshire, UK). As a control, commercial 
pooled AB serum was used (Human serum type AB, Cat# 14-490E, BioWhittaker, Lonza, 
MD, USA). This was to be able to have sufficient plasma for all set-up experiments. We later 
tested (unpurified) maternal plasma from HPA-1a immunized mothers, collected from the 
biobank in the Stockholm laboratory. These samples had different levels of anti-HPA-1a, and 
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also other antibodies (IgM, anti-HLA class I antibodies) could be present in the plasma. As 
control for these experiments, AB plasma from a single donor was used. In a final round of 
experiments, purified IgG from immunized mothers (screened negative for anti-HLA class I 
antibodies) were used, with purified IgG from AB plasma as control. The IgG was purified 
from plasma using affinity chromatography (MAbTRAP kit with HiTrap Protein G HP 
columns, GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
For these experiments we tested platelet function in Multiplate (with ADP and TRAP as 
stimuli), and CD62-P up-regulation using flow cytometry. We hypothesized that the anti-
HPA-1a antibodies could interfere with aggregation by blocking fibrinogen binding. Integrin 
outside-in signaling may stimulate the release of α-granules and CD62-P up-regulation[133], 
and we hypothesized that in the presence of anti-HPA-1a antibody, this could be reduced.  
When using monoclonal anti-HPA-1a antibody (26-4), we decided to investigate the effects 
of anti-HPA-1a antibodies on fibrinogen binding, CD62-P up-regulation, and hemostatic 
effects in Rotem (as this assay depends more on fibrinogen, and reduction of aggregation in 
Multiplate had already been published). 
 
7.10 STATISTICS 
Data was analyzed using different versions of SPSS software (SPSS Inc., Chicago, IL, USA). 
Figures were created in SPSS, Microsoft Excel for Mac 2011, Prism 6 for Mac OS X, Plotly 
(plot.ly), and Adobe Photoshop for Windows. 
Normality of distribution was evaluated graphically, and tested by Shapiro-Wilks and 
Kolmogorov-Smirnov tests, depending on size of the data. For continuous variables, 
independent samples t-test was used to compare means for data with normal distribution, 
while for variables without a normal distribution, Mann-Whitney U test was used. Similarly, 
One-Way ANOVA with Bonferroni post-hoc test or Kruskal-Wallis with Dunn-Bonferroni 
post-hoc test was used for comparison of continuous variables between groups. For 
comparisons within groups, Wilcoxon signed rank test was used. Chi-square and Fisher’s 
exact tests was used for comparing frequencies for categorical variables, depending on size of 
the data. For correlations, we report Pearson’s or Spearman’s correlation coefficients, 
depending on distribution of the data. Missing data was treated by pairwise deletion when 
comparing unadjusted data, and by listwise deletion for regression analyses. Level of 
significance was set at a p-value of <0.05. 
Binary logistic regression models were used to examine associations of different clinical 
variables. Similar ICD-10 SE codes were categorized into groups, while continuous variables 
were for the most part kept continuous. In study IV, the reported model investigating 
increasing odds of seizures with increasing gestational age, birth-weight was included as an 
independent variable. For the odds of trauma, birth-weight, asphyxia, and vacuum delivery 
were set as independent variables. 
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7.11 STUDY DESIGN 
Study I and II can both be classified as comparative cross-sectional studies. Cross-sectional 
studies are characterized by simultaneous measure of exposure (anti-HLA class I antibodies) 
and outcome (thrombocytopenia) in a given period, although the point of measurement does 
not need to be at the same time point for all cases. Cases in study I and II were based on 
selected referrals for FNAIT, over a six and eleven-year period, respectively, but exposure 
and outcome were measured at the same time for each case. The lack of latency period 
between exposure and observed outcome makes any causal inference problematic (although it 
can be assumed that the antibodies were present during pregnancy).  
The control groups in both studies were collected prospectively, and were used to compare to 
the case groups. In study I, no clinical data was available on the controls, but the samples 
were from mothers with healthy pregnancies, where neonatal thrombocytopenia would not be 
expected. In study II, the control samples were collected from a prospective study [238, 239], 
and 45 of the 60 controls included in the study were randomly selected and checked; none of 
these control neonates were thrombocytopenic. 
Since FNAIT due to anti-HLA class I alloantibodies likely could be considered a subgroup of 
a rare condition, a cross-sectional study design based on national referrals for FNAIT is an 
efficient approach. A cohort study, for instance comparing data on all deliveries with and 
without maternal anti-HLA class I antibodies, would be better suited to answer the main 
research question of the effect of anti-HLA class I antibodies during pregnancy, but would 
require large resources. Although flawed with regards to inference of causality, the selected 
study design allowed for a thorough description of a rare case group.   
Study IV is a register-based study, where cases were identified by the presence of an outcome 
(ICH), and then checked for exposure (maternal anti-HPA antibodies) at a later time-point. 
This is at first glance similar to a case-control study, where study subjects are classified by 
their outcome, before checking for exposure. However, we lack data on maternal platelet 
alloantibodies (exposure) in a control group of neonates without ICH; the registry-approach 
doesn’t yield any control group since all cases were selected due to the presence of the 
outcome. An alternative approach would have been to also sample mothers who had given 
birth to healthy children in the same period, and use this data as a control group in a case-
control study. 
In a cohort study, study subjects are classified according to exposure, and then investigated 
for the outcome. To perform study IV as a cohort study, we would have had to investigate all 
mothers in a study population for anti-HPA antibodies (exposure), and then compare the 
frequency of neonatal ICH (outcome) among exposed and non-exposed. For instance, by 
using routine samples taken during pregnancy for anti-HPA antibody testing, and connecting 
this data with register data on neonatal ICH. However, this would be more time consuming 
and require a lot of resources, as both maternal anti-HPA antibodies and neonatal ICH are 
rare events.  
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The final study design is most similar to a comparative cross-sectional design, since it 
describes both outcome and exposure in a certain population at a given time: We use clinical 
data for the background population (all deliveries in Sweden) as a comparative control. 
Although exposure and outcome were not registered simultaneously, one could argue that the 
risk of immunization is mainly determined by maternal HPA-1a antigen status, which will 
remain unchangeable over time. 
Assuming all cases of neonatal ICH in Sweden were registered, the register-based approach 
could give an indication of prevalence of neonatal ICH in the study period, and the 
prevalence of ICH associated with FNAIT. However, this assumption does not hold, as 
asymptomatic cases of ICH were likely missed. Moreover, we could not assess incidence of 
ICH due to FNAIT, as the mothers were investigated for alloantibodies years after delivery, 
and as such there was no assessable latency time between exposure and outcome. But, given 
these limitations, we could give a good estimate of the frequency of FNAIT in clinically 
recognized cases of ICH. Since all samples were typed for the HPA-1a antigen, we could at 
least exclude the most common cause of FNAIT in Sweden in the majority of investigated 
cases. Both neonatal ICH as outcome and maternal platelet antibodies as exposure are 
difficult to assess, especially retrospectively. 
The “ideal” approach to assess incidence of ICH due to FNAIT would have been to 
prospectively sample the mothers during pregnancy and in connection with delivery, and 
screen all neonates for the presence of ICH and thrombocytopenia. This would however 
demand significant resources, and comes with considerable ethical considerations.    
 
7.12 SELECTION BIAS 
Both study I and II have an inherent selection bias, in that cases were selected based on 
national referrals for FNAIT. In the absence of screening for thrombocytopenia, only 
neonates with clinical symptoms (which could be related to other causes, as revealed in study 
I), were available for study. Different practices and clinical awareness of FNAIT at the 
hospitals could also affect the referral of cases. Mild cases of transient thrombocytopenia 
could perhaps be less likely to be referred, as compared to cases with severe 
thrombocytopenia in more complicated cases. Without screening, FNAIT is thought to be 
underdiagnosed[240], and the low platelet counts in our cases (medians 30 and 24x109/L in 
study I and II, respectively) could perhaps reflect a selection bias towards the more severe 
cases. This kind of bias is one of the common pitfalls of the chosen retrospective study 
design, but a retrospective study was necessary considering FNAIT due to anti-HLA class I 
antibodies is a rare entity. 
The control groups were prospectively collected without any criteria for selection, and were 
consequently not affected by selection bias. However, the cases were referred nationally, and 
both control groups were recruited locally. In study II, the control group was therefore 
validated against the Medical Birth Registry of Norway (MBRN), to ensure that the controls 
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were representative of the general Norwegian population in the study period. The 
geographical location of these studies is worth considering, since allele frequencies vary 
across different populations, and the results should therefore be generalized to other 
populations with caution.  
Study IV could also suffer from selection bias. Mothers of neonates registered with ICH were 
contacted and asked to provide samples, and it is difficult to know who would be more or less 
inclined to participate, and how this affected our results. While some expressed gratitude for 
the study, others declined to participate due to previous negative experiences with the health 
services. Comparing the clinical data available, there was a tendency towards less response 
from cases with more severe morbidity, and so there is a possible bias towards less 
complicated cases.  
 
7.13 SAMPLING TIME 
In study I, controls where sampled in conjunction with delivery, while the time from delivery 
to sampling varied considerably for cases. The median was 4.5 days after delivery, with two 
cases sampled years after, in the subsequent pregnancy. In study II, the controls were sampled 
during pregnancy, at 22-24 weeks of gestation. For the cases, similarly to study I, samples 
were taken after delivery as part of investigation for FNAIT, with median 6 days after 
delivery, and only four cases longer than 15 days after delivery (max 401 days). In study IV, 
the mothers were sampled several years after delivery, with the oldest child born 2003, while 
the sampling occurred during 2015. 
There are three main problems with different sampling times in study I and II: Firstly, one 
can question whether the antibodies present in maternal circulation early in gestation really 
reflect immunization due to the current, and not any previous pregnancy. Secondly, 
antibodies detected after delivery could have higher levels due to the delivery itself. Anti-
HLA class I antibodies have been shown to be detectable earlier than week 20[241], so 
samples taken at 22-24 weeks should reflect immunization in the ongoing pregnancy. On the 
other hand, later sampling could have led to more antibody-positive controls, due to an 
increased exposure of fetal antigens to the maternal immune system. As we only detected 
IgG, it is likely that the antibodies arose from a primary immunization due to a pregnancy, 
rather than due to delivery, since isotype switching from IgM to IgG usually takes longer than 
a week. However, a secondary immunization due to the delivery could theoretically increase 
the antibody levels rapidly[242]. 
The third problem with different sampling times is that levels of maternal alloantibodies may 
fluctuate during pregnancy. They may both decrease with increased placental transfer of 
antibody, and increase with increased exposure of fetal cells later in pregnancy, or after the 
loss of the placenta as an absorptive surface after delivery. Differences in sampling time may 
therefore affect the comparisons of antibody levels in unpredictable ways. Since all controls 
were sampled at the same time, we could not adjust for the differences in sampling time, but 
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antibody levels and time after delivery for the cases were not significantly correlated (study 
I). In study II, longitudinal samples were available for seven controls, and samples taken 
during pregnancy showed 66% higher MFI levels than those taken after delivery (mean ratio 
1.66, 95% CI 0.94-2.38), suggesting that variation in sampling time actually lead to an 
underestimation of the differences in antibody levels. It is however important to note that a 
higher level may be due to both increased antibody production, and decrease in placental 
transfer, and ideally, anti-HLA class I antibody levels should also be quantified in the 
neonate, for instance in umbilical cord blood. To conclude, it is unlikely that differences in 
sampling time affected the comparison of antibody levels between cases and controls, but it is 
important to keep these considerations in mind if one were to try and draw any causal 
inference from these studies. 
In study IV, the mothers were sampled several years after delivery. Anti-HPA-1a antibodies 
have been shown to increase postpartum [109], and can persist for years [106]. The study 
focused on anti-HPA-1a immunization, and all mothers were typed for the HPA-1a antigen. 
A late sampling was therefore not a concern for the detection of anti-HPA-1a antibodies in 
this study. It is not known how levels of the other anti-HPA change over time, but with 
sensitive detection methods, and the assumption that also other anti-HPAs can persist long 
after pregnancy, a late sampling of mothers does not seem a major concern, although it 
cannot be excluded that some cases were missed due to the long interval from delivery to 
sampling.  
 
7.14 OTHER CAUSES OF THROMBOCYTOPENIA AS CONFOUNDING 
FACTORS IN STUDY I AND II 
A confounding factor is defined as a factor affecting both the exposure (for instance anti-
HLA class I antibodies) and outcome (neonatal thrombocytopenia). When selecting cases 
with suspected FNAIT based on referrals, there is a risk of including cases with neonatal 
thrombocytopenia caused by other factors, as evident in study I. In study II, such factors were 
to a certain extent excluded, but many of the children were small for gestational age (SGA), 
and had suffered from asphyxia. Both asphyxia[243] and SGA[244], which can be a result of 
IUGR, has been associated with thrombocytopenia. SGA and asphyxia are in themselves not 
confounding factors, as they don’t lead to anti-HLA class I immunization, but they could 
point towards another underlying condition, such as inflammation during pregnancy, which 
could be associated with both increased levels of anti-HLA class I antibodies[245] and 
thrombocytopenia[112, 246]. Unfortunately, we could not assess maternal inflammatory 
markers in our studies. Any future prospective studies should consider including such 
measures. 
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8 CONCLUDING REMARKS 
 
FNAIT is a heterogeneous condition, where multiple mechanisms may be involved. The 
outcome likely depends on the alloantibodies involved, which may exert different effects 
depending on affinity, composition, titer, and specificity, but neonatal factors likely also play 
a role. FNAIT is as such not one single entity, which hampers any prediction of outcome 
based on one particular parameter. 
Study III, on anti-HPA-1a antibodies and neonatal platelets, indicate that platelet function 
could be affected in FNAIT, by a decreased ability to bind fibrinogen in the presence of anti-
HPA-1a antibody. However, any consequences on neonatal hemostasis need further studies to 
be ascertained. A better understanding of the neonatal platelet function in FNAIT could 
impact treatment strategies. 
The two studies on anti-HLA class I antibodies and FNAIT (study I and II) thorougly 
describe a rare group of cases, and although limited by the retrospective study design, the 
studies show that these cases can have a severe outcome, and that clinical data also needs to 
be thorougly investigated in such cases. In both studies we found that the referred cases had 
higher levels of anti-HLA class I antibodies compared to controls, and a high frequency of 
nulliparous mothers, which could imply an aberrant breach of maternal tolerance with 
negative effects on the fetus. We were able to disentangle the anti-HLA class I antibody 
patterns, which will be a useful tool in future studies, and may also be of use in other settings. 
Nonetheless, it is obvious from these studies that large, prospective investigations are 
necessary to study any causal association between anti-HLA class I antibodies and FNAIT. 
The study on intracranial hemorrhages and FNAIT (study IV) showed a vast number of 
factors associated with ICH in neonates born close to term, and very few identified cases with 
maternal platelet alloimmunization. This indicates that cases of FNAIT, even when 
manifested as an ICH, are difficult to identify retrospectively, and could perhaps indicate a 
lower frequency of ICH due to FNAIT than previously assumed.   
Study of referred cases of FNAIT need to continue; without screening studies these cases are 
the only way to gain deeper knowledge on the clinical course of FNAIT. Clinical awareness 
of FNAIT is therefore important, not only for the individual case, but also because there is 
still much to learn and explore.  
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9 FUTURE PERSPECTIVES 
 
In order to better understand the impact of anti-HLA class I antibodies on pregnancy, a large, 
international, prospective study is needed. Such a study should include genotyping of mother, 
neonate, and preferably also father, in addition to extensive clinical data on mother and 
neonate. From laboratory data, it would also be helpful to include not only hematological 
parameters, but also inflammatory markers, both from maternal samples during pregnancy, 
and from neonatal or cord blood samples, to see how and if inflammation relates to both anti-
HLA class I alloimmunization and thrombocytopenia. If using routine samples taken during 
pregnancy and cord blood samples, such a study would not be physically invasive, although it 
would require extensive resources. Most likely a large number of cases would have to be 
included, considering the high frequency of anti-HLA class I antibodies in normal 
pregnancies, as compared to the rare occurrence of FNAIT.   
It would also be useful to test for anti-αvβ3 antibodies in a large cohort of unselected 
pregnancies, to learn more about the frequency of these antibodies, and how their presence 
relates to clinical outcome. Furthermore, testing for these antibodies should already be 
implemented in routine work-ups of anticipated and suspected cases of FNAIT, as their 
presence could be associated with an ICH. If the ratio between anti-αvβ3, anti-β3, and anti-
αIIbβ3 types of anti-HPA-1a antibodies could be determined in a prospective setting, by for 
example longitudinal sampling of mothers during pregnancy and after delivery, this could 
indicate whether platelets or trophoblast represent the immunizing source in FNAIT. Effects 
of anti-HPA-1a antibodies on placental function should also be investigated in this regard; 
through histopathological investigation of placentas, one could see if inflammatory changes, 
as previously reported in cases of FNAIT, corresponded with the presence and level of 
maternal anti-αvβ3 antibodies.  
Investigation of anti-HPA-1a antibody glycosylation patterns and relation to clinical outcome 
should also be performed in a prospective setting. This is a promising diagnostic marker, but 
the current studies are performed on retrospectively identified cases. In addition, further 
studies on the B-cell machinery responsible for the antibody glycosylation would be 
interesting, to better understand the mechanisms involved and how they are regulated. 
The possibility that neonatal platelet function could play a role in FNAIT should also be 
investigated further, both by investigating the available monoclonal antibody in other 
functional assays, and by developing and testing other monoclonal anti-HPA-1a antibodies. 
Testing neonatal platelet function in cases of suspected FNAIT could be problematic, 
especially with regards to sampling from a thrombocytopenic neonate, but flow cytometry 
based assays require only small volumes of blood, and could possibly be used to guide 
treatment.  
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10 POPULAR SCIENCE SUMMARY 
 
Picture a baby in the womb, which have inherited its 
unique traits from both the mother and father. Similar to 
how a kidney transplant is sometimes rejected, your 
mother’s immune system might reject the parts of you that 
are inherited from your father. In fetal and neonatal 
alloimmune thrombocytopenia (FNAIT), the maternal 
immune system reacts to proteins inherited from the father 
that are expressed on fetal platelets. Maternal antibodies 
directed against fetal platelets are then carried across the 
placenta to the baby, where they can cause destruction of 
platelets.  
Platelets, or thrombocytes, are small cells in your blood 
that are necessary for a successful clot formation. When a 
baby is born with a low number of platelets, it therefore 
runs the risk of bleedings.  
Nearly a third of all mothers produce antibodies during pregnancy; in rare cases these 
antibodies target particular cells in the baby, such as platelets, and lead to their destruction, 
but in many cases we don’t know their exact role or consequence, as they target surface 
proteins found on almost all cell types. We don’t know if these more commonly detected 
antibodies also can lead to destruction of a baby’s platelets, or if they are just a normal 
finding. If these antibodies in fact also can cause harm, it would change the way we monitor 
and treat these mothers and their newborns.  
We studied this common type of antibodies found after pregnancy (HLA class I antibodies). 
Based on cases referred due to low platelet counts in the newborn, we compared antibodies in 
mothers of children with low platelet numbers to antibodies in control mothers with healthy 
babies. In the studies, we found that the mothers with sick babies had higher levels of 
antibodies (study I and II), and that the antibodies were specific against cell surface proteins 
inherited from the father (study II). We also found that many of these babies had other 
complications that could contribute to a low number of platelets. A high concentration of 
antibodies could be associated with a worse pregnancy outcome, but we need larger studies to 
decide if the antibodies actually cause a low platelet count number, or if they are a sign of 
another underlying condition.  
In an experimental study, we investigated how a type of platelet-specific antibodies (HPA-1a 
antibody) affected the platelets’ ability to form a blood clot (study III). The antibody inhibited 
binding of fibrinogen, a protein central for successful clot formation as it binds activated 
platelets together and further enhances their activation. We also compared adult and newborn 
blood platelets (using umbilical cord blood), and found that newborn platelets reacted less to 
stimuli. Together, this could in theory mean that less reactive platelets in the newborn are 
Figure 17 
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particularly susceptible to the effects of anti-platelet antibodies, which could aggravate the 
bleedings in FNAIT; this possibility needs to be tested further. 
Finally, we looked for antibodies directed against fetal platelets in mothers of newborns who 
had been diagnosed with a bleeding in the brain, or intracranial hemorrhage (ICH), which is 
the most feared type of bleeding complication (study IV). These types of bleedings are rare in 
newborns born near term, so the babies were identified using a register on neonatal health in 
Sweden. Between 2003 and 2012, 286 babies with ICH were registered, and we contacted the 
mothers for samples during the year 2015. Out of 105 included samples, we found only three 
mothers with platelet-specific antibodies. The most common antibody known to cause a low 
platelet number (anti-HPA-1a), was only found in one mother. Due to the long interval 
between the birth of the children and sampling of the mothers, the more rare antibodies could 
not be excluded. Still, we could exclude the most common cause of FNAIT (anti-HPA-1a) in 
the majority of cases investigated by analyzing the mothers’ own platelet type. We also 
reviewed clinical data from the register and hospital records, and found that low number of 
platelets in general were rare. This could mean that FNAIT is a rare cause of ICH, or that we 
missed cases of FNAIT due to how we conducted the study – for instance only symptomatic 
children would be diagnosed and registered, and we excluded those born very prematurely 
(before week 32). This could have implications for any future screening programs for 
FNAIT. 
Together, these studies confirm the notion that FNAIT is a complicated condition, and that 
outcome likely depends on the different kinds of antibodies involved, in addition to factors in 
the newborn. Due to the potential severity of FNAIT, further studies are needed, and results 
from these studies can be used to inform future investigations.  
 
Figure 17: Janeway’s Immunobiology, 8th edition [247]. 
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11 POPULÆRVITENSKAPELIG SAMMENDRAG PÅ NORSK 
 
Et barn vil alltid arve litt fra mor og litt fra far. I noen 
sjeldne tilfeller kan mors immunsystem gjenkjenne deler 
av det som er arvet fra far som fremmed under 
graviditeten. Ved føtal og neonatal alloimmun 
trombocytopeni (FNAIT) reagerer mors immunforsvar på 
blodplate-proteiner arvet fra far. Mors antistoffer, rettet 
mot barnets blodplater, overføres via morkaken til barnet, 
der de kan forårsake ødeleggelse av blodplater. 
Blodplater, også kalt trombocytter, er små celler i blodet 
som er nødvendige for at blodet skal kunne størkne, eller 
koagulere. Når et barn fødes med et lavt antall blodplater, 
har det derfor en økt risiko for blødninger.  
Nesten en tredjedel av alle mødre produserer antistoffer i 
forbindelse med svangerskapet. I sjeldne tilfeller er disse 
antistoffene rettet mot bestemte celler i barnet, som blodplater, men i mange tilfeller vet vi 
ikke nøyaktig betydningen av disse antistoffene, ettersom de kan være rettet mot proteiner 
som finnes på nesten alle kroppens celler. Vi vet altså ikke om de vanligste detekterte 
antistoffene også kan føre til ødeleggelse av blodplater, eller om de bare er et tilfeldig funn. 
Hvis disse antistoffene faktisk kan forårsake skade, vil det ha betydning for måten vi 
behandler og følger opp disse mødrene og deres nyfødte. 
Vi undersøkte den vanlige typen av antistoffer som man finner etter graviditet (HLA klasse I 
antistoffer). Basert på et utvalg av nyfødte som ble henvist på grunn av lavt antall blodplater, 
sammenlignet vi antistoffer hos mødre til barn med lavt antall blodplater med antistoffer hos 
mødre med friske barn. I to studier fant vi at mødrene med syke babyer hadde en høyere 
konsentrasjon av antistoffer (studie I og II), og at antistoffene var spesifikke mot proteiner 
arvet fra far (studie II). Vi fant også at mange av disse babyene hadde andre komplikasjoner 
som kunne bidra til et lavt antall blodplater. En høy konsentrasjon av antistoffer kan være 
forbundet med risiko for sykdom, men vi trenger større studier for å bestemme om 
antistoffene faktisk forårsaker et lavt antall blodplater, eller om de er et tegn på en annen, 
underliggende tilstand. 
I en eksperimentell studie undersøkte vi hvordan en type blodplate-spesifikke antistoffer 
(HPA-1a antistoff) påvirket blodplatenes evne til å koagulere (studie III). Antistoffet hemmet 
binding av fibrinogen til blodplatene, et protein som hjelper blodplatene til å klistre seg 
sammen og aktiveres, og som dermed er viktig for en vellykket koagulering. Vi 
sammenlignet også blodplater fra voksne og nyfødte (ved bruk av navlestrengsblod), og fant 
at nyfødtes blodplater reagerte mindre på stimuli sammenlignet med voksne. Dette kan i 
teorien bety at blodplater hos nyfødte er spesielt utsatt for virkningene av antistoffer rettet 
mot blodplater, noe som kan forverre blødninger. Denne muligheten bør undersøkes videre, 
ettersom det kan påvirke behandlingen av blødninger ved FNAIT. 
Figur 17 
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Til slutt lette vi etter antistoffer rettet mot barns blodplater hos mødre til nyfødte som hadde 
blitt diagnostisert med hjerneblødning, som er den mest alvorlige blødningskomplikasjonen 
ved FNAIT (studie IV). Barna ble identifisert ved hjelp av et nasjonalt register over nyfødtes 
helse i Sverige, ettersom slike blødninger er sjeldne hos nyfødte som er født mot slutten av 
svangerskapet. I perioden fra 2003 til 2012 var 286 barn registrert med hjerneblødning, og vi 
kontaktet mødrene for prøver i løpet av 2015. Av 105 inkluderte blodprøver fant vi bare tre 
mødre med blodplate-spesifikke antistoffer. Det vanligste antistoffet kjent for å forårsake 
FNAIT (HPA-1a antistoff), ble bare funnet hos én mor. Siden det gikk lang tid fra da barna 
ble født til prøvetaking av mødrene, kunne vi ikke utelukke de sjeldneste antistoffene, men vi 
kunne utelukke den vanligste årsaken til FNAIT ut ifra hvilken type blodplate mor hadde. Vi 
undersøkte også kliniske data fra registeret og sykehusjournaler, og fant at et lavt antall 
blodplater hos disse nyfødte var sjeldent. Dette kan bety at FNAIT er en sjelden årsak til 
hjerneblødning, eller at vi gikk glipp av tilfeller av FNAIT på grunn av hvordan vi 
gjennomførte studien - for eksempel vil bare barn med symptomer bli diagnostisert og 
registrert, og vi undersøkte ikke de som ble født veldig prematurt (før uke 32). Resultatene fra 
studien kan påvirke hvordan fremtidige screeningsprogrammer for FNAIT utføres. 
Sammen bekrefter disse studiene at FNAIT er en sammensatt tilstand, og at utfallet 
sannsynligvis avhenger av hvilken type antistoff som involvert, i tillegg til faktorer hos den 
enkelte nyfødte. FNAIT er potensielt veldig alvorlig, og det er fortsatt mye man ikke vet. 
Resultater fra disse studiene kan være til nytte for fremtidige studier. 
 
Figur 17: Janeway’s Immunobiology, 8th edition [247]. 
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